[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4291
6. Chen WC, Completo GC, Sigal DS, Crocker PR, Saven A, Paulson JC: In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood; 2010 Jun 10;115(23):4778-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo targeting of B-cell lymphoma with glycan ligands of CD22.
  • Antibody-mediated cell depletion therapy has proven to provide significant clinical benefit in treatment of lymphomas and leukemias, driving the development of improved therapies with novel mechanisms of cell killing.
  • A current clinical target for B-cell lymphoma is CD22, a B-cell-specific member of the sialic acid binding Ig-like lectin (siglec) family that recognizes alpha2-6-linked sialylated glycans as ligands.
  • Here, we describe a novel approach for targeting B lymphoma cells with doxorubicin-loaded liposomal nanoparticles displaying high-affinity glycan ligands of CD22.
  • The targeted liposomes are actively bound and endocytosed by CD22 on B cells, and significantly extend life in a xenograft model of human B-cell lymphoma.
  • Moreover, they bind and kill malignant B cells from peripheral blood samples obtained from patients with hairy cell leukemia, marginal zone lymphoma, and chronic lymphocytic leukemia.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Doxorubicin / pharmacokinetics. Drug Delivery Systems / methods. Lymphoma, B-Cell / drug therapy. Polysaccharides / agonists. Sialic Acid Binding Ig-like Lectin 2

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Med. 2008;59:237-50 [18186705.001]
  • [Cites] Nat Rev Drug Discov. 2005 Feb;4(2):145-60 [15688077.001]
  • [Cites] J Control Release. 2008 Feb 18;126(1):50-8 [18068849.001]
  • [Cites] Immunology. 2008 Mar;123(3):314-25 [18067554.001]
  • [Cites] PLoS One. 2008;3(4):e1967 [18414664.001]
  • [Cites] J Am Chem Soc. 2008 May 28;130(21):6680-1 [18452295.001]
  • [Cites] Clin Lymphoma Myeloma. 2008 Feb;8(1):21-32 [18501085.001]
  • [Cites] J Am Chem Soc. 2008 Jun 18;130(24):7736-45 [18505252.001]
  • [Cites] Exp Hematol. 2008 Jul;36(7):755-68 [18565392.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6300-5 [18676854.001]
  • [Cites] PLoS One. 2009;4(1):e4171 [19137069.001]
  • [Cites] Curr Pharm Des. 2009;15(2):153-72 [19149610.001]
  • [Cites] Trends Pharmacol Sci. 2009 May;30(5):240-8 [19359050.001]
  • [Cites] Exp Mol Pathol. 2009 Jun;86(3):215-23 [19186176.001]
  • [Cites] Med Res Rev. 2010 Mar;30(2):270-89 [19626595.001]
  • [Cites] Cancer Lett. 2008 Feb 18;260(1-2):137-45 [18077084.001]
  • [Cites] Curr Opin Chem Biol. 2004 Dec;8(6):617-25 [15556405.001]
  • [Cites] Blood. 1994 Aug 1;84(3):702-7 [7519071.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1476-87 [10778980.001]
  • [Cites] Blood. 2001 Jan 1;97(1):288-96 [11133773.001]
  • [Cites] Blood. 2001 Jan 15;97(2):528-35 [11154233.001]
  • [Cites] Biochemistry. 2001 May 22;40(20):5964-74 [11352731.001]
  • [Cites] N Engl J Med. 2001 Jul 26;345(4):241-7 [11474661.001]
  • [Cites] Med Oncol. 2002;19(1):55-8 [12025891.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1845-8 [12168880.001]
  • [Cites] J Am Chem Soc. 2002 Dec 18;124(50):14922-33 [12475334.001]
  • [Cites] Structure. 2003 May;11(5):557-67 [12737821.001]
  • [Cites] Lancet. 2003 Jul 12;362(9378):139-46 [12867117.001]
  • [Cites] Methods Enzymol. 2003;373:3-16 [14714393.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6104-9 [15079087.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2662-70 [15226333.001]
  • [Cites] Am J Clin Pathol. 2005 Jun;123(6):826-32 [15899772.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):242-9 [16397048.001]
  • [Cites] Mol Cell Biol. 2006 Feb;26(4):1549-57 [16449664.001]
  • [Cites] Mol Cancer Ther. 2006 Apr;5(4):818-24 [16648551.001]
  • [Cites] J Immunol. 2006 Sep 1;177(5):2994-3003 [16920935.001]
  • [Cites] J Immunol. 2006 Sep 1;177(5):3063-73 [16920943.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8740-8 [16951190.001]
  • [Cites] Nat Rev Immunol. 2007 Apr;7(4):255-66 [17380156.001]
  • [Cites] Mol Cell Biol. 2007 Aug;27(16):5699-710 [17562860.001]
  • [Cites] Int J Nanomedicine. 2006;1(3):229-39 [17717964.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2240-5 [17657218.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:233-42 [18024635.001]
  • [Cites] Exp Eye Res. 2008 Jan;86(1):138-49 [18036523.001]
  • [Cites] Int J Cancer. 1990 Mar 15;45(3):481-5 [2307538.001]
  • [Cites] Blood. 1993 Aug 15;82(4):1277-87 [7688993.001]
  • [Cites] Biochim Biophys Acta. 1993 Sep 19;1151(2):201-15 [8373796.001]
  • [CommentIn] Expert Rev Vaccines. 2010 Nov;9(11):1251-6 [21087105.001]
  • [CommentIn] Blood. 2010 Jun 10;115(23):4626-7 [20538811.001]
  • [ErratumIn] Blood. 2011 May 19;117(20):5551
  • (PMID = 20181615.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA138891; United Kingdom / Wellcome Trust / / 081882; United States / NIAID NIH HHS / AI / R01 AI050143; United States / NIAID NIH HHS / AI / R01-AI050143; United States / NIGMS NIH HHS / GM / R01 GM060938; United States / NIGMS NIH HHS / GM / R01-GM060938
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / CD22 protein, human; 0 / Ligands; 0 / Liposomes; 0 / Polysaccharides; 0 / Sialic Acid Binding Ig-like Lectin 2; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ PMC2890185
  •  go-up   go-down


7. Miltényi Z, Simon Z, Páyer E, Váróczy L, Gergely L, Jóna A, Illés A: [Changing patterns in the clinical, pathological features of Hodgkin lymphoma]. Orv Hetil; 2010 Dec 5;151(49):2011-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changing patterns in the clinical, pathological features of Hodgkin lymphoma].
  • [Transliterated title] Változnak-e a Hodgkin-lymphoma klinikopatológiai jellemzői?
  • Hodgkin lymphoma shows a well-known geographic pattern, but temporal changes have been found recently as well.
  • PATIENTS AND METHODS: The Authors analyzed 439 Hodgkin lymphoma patients' clinicopathological and treatment data.
  • RESULTS: The first period contained 117 patients, the second 147 and third 115 Hodgkin lymphoma patients.
  • CONCLUSIONS: Changes can be explained by the altered nature of Hodgkin lymphoma, the changes in socioeconomic status and the development of diagnostic and therapy methods.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21106481.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


8. Gleissner B, Zwick C, Pfreundschuh M: [Treatment of diffuse large B-cell lymphoma]. Dtsch Med Wochenschr; 2008 Sep;133(36):1785-94; quiz 1795-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of diffuse large B-cell lymphoma].
  • Diffuse large B-cell lymphoma represent 40% of all lymphoma.
  • The development of dose-dense chemotherapeutic regimens and the application of the monoclonal CD20 antibody rituximab improve the prognosis significantly.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunologic Factors / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18767006.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 20
  •  go-up   go-down


9. Charavin-Cocuzza M, Templier I, Simon A, Salameire D, Cuchet E, Reymond JL, Beani JC, Leccia MT: [Febrile cellulitis surrounding a scar revealing a large immunoblastic B-cell lymphoma]. Ann Dermatol Venereol; 2008 Dec;135(12):848-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Febrile cellulitis surrounding a scar revealing a large immunoblastic B-cell lymphoma].
  • BACKGROUND: Secondary skin sites of lymphoma appear in the advanced stages of the disease.
  • We report the first case of a pericicatricial skin infiltration, mimicking febrile dermohypodermitis, revealing diffuse immunoblastic large B-cell non-Hodgkin's lymphoma.
  • Histological analysis and immunolabelling pointed to immunoblastic large B-cell non-Hodgkin's lymphoma.
  • DISCUSSION: Secondary skin manifestations of lymphoma are generally non-specific (pruritus, ichthyosis, purpura, etc.) rather than specific in terms of lymphoid infiltration.
  • As in our patient, certain cutaneous sites of lymphoma may have a misleading clinical presentation, histological analysis alone was able to provide a conclusive diagnosis.
  • In our patient, the highly specific infiltration seen around the entire scar could either suggest a Koebner phenomenon or point to a role of the cutaneous aggression within the development of an inflammatory process contributing to pericicatricial infiltration by lymphoid cells.
  • [MeSH-major] Cellulitis / diagnosis. Head and Neck Neoplasms. Lymphoma, B-Cell. Lymphoma, Large-Cell, Immunoblastic. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Cellulitis.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19084696.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


10. Cendras J, Sparsa A, Bedane C, Delage M, Touati M, Bonnetblanc JM: [Primary cutaneous large B-cell lymphoma in chronic venous leg ulcer]. Ann Dermatol Venereol; 2007 Apr;134(4 Pt 1):357-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cutaneous large B-cell lymphoma in chronic venous leg ulcer].
  • BACKGROUND: Large B-cell lymphoma of the leg in elderly subjects, of intermediate prognosis according to the new EORTC classification, may present as nodular or ulcerated forms.
  • We report the case of an elderly man with chronic leg ulcer, recently undergoing modification, in which microscopy revealed large B-cell lymphoma (CD20-).
  • Histological examination of a skin biopsy revealed the presence of large B-cell lymphoma and immunohistochemical analysis showed positive anti-CD79a+, CD20- antibody labeling of cells.
  • DISCUSSION: Many causal links have been proposed between large B-cell lymphoma of the leg and aetiologies such as infectious agents, Koebner phenomenon and chronic lymphedema, as well as various other vascular factors.
  • It may have been leg ulcer cutaneous B-cell lymphoma, or, more likely, development of lymphoma on a chronic mixed ulcer, with the respective roles of vascular disease, local immunosuppression and antigenic stimulation subject to debate.
  • [MeSH-major] Leg Ulcer / etiology. Lymphoma, B-Cell / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483756.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD20; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down


11. Greve J, Bas M, Schipper J, Hoffmann TK: [Primary cutane manifestation of a precursor-B-lymphoblastic lymphoma in the external ear]. Laryngorhinootologie; 2008 Oct;87(10):728-30
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cutane manifestation of a precursor-B-lymphoblastic lymphoma in the external ear].
  • A Non-Hodgkin Lymphoma (NHL) represents nearly three percent of all malignant tumors.
  • We report on an extranodal B-cell-lymphoma of the ear in a young woman.
  • This infection led to the development of a massive ear tumor.
  • In spite of the considerable extent of the lymphoma there was no systemic manifestation and a total remission was induced by chemotherapy before adjuvant radiation.
  • [MeSH-major] Ear Neoplasms / diagnosis. Ear, External. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633860.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Fischer M, Grünwald F, Knapp WH, Trümper L, von Schilling C, Dreyling M, Deutsche Gesellschaft für Nuklearmedizin, Deutsch Gesellschaft für Hämatologie und Onkologie: [Guideline for radioimmunotherapy of CD20+ follicular B-cell non-Hodgkin's lymphoma]. Nuklearmedizin; 2009;48(6):215-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Guideline for radioimmunotherapy of CD20+ follicular B-cell non-Hodgkin's lymphoma].
  • This guideline is a prerequisite for the quality management in the treatment of non-Hodgkon-lymphomas in patients with relapsed or refractory follicular lymphoma after rituximab therapy and as consolidation therapy after first remission following CHOP like treatment using radioimmunotherapy.
  • The complete treatment inclusive after-care has to be realised in close cooperation with those colleagues (hemato-oncologists) who propose, in general, radioimmunotherapy under consideration of the development of the disease.
  • [MeSH-major] Antigens, CD2 / immunology. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / radiotherapy. Nuclear Medicine / standards. Quality Assurance, Health Care / standards. Radiation Oncology / standards. Radioimmunotherapy / standards

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19902120.001).
  • [ISSN] 0029-5566
  • [Journal-full-title] Nuklearmedizin. Nuclear medicine
  • [ISO-abbreviation] Nuklearmedizin
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Practice Guideline
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD2
  •  go-up   go-down


13. Vitolo U, Ferreri AJ, Montoto S: Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia. Crit Rev Oncol Hematol; 2008 Aug;67(2):172-85
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
  • In the WHO classification, WM is associated to lymphoplasmacytic lymphoma (LPL); it is a clinicopathologic entity characterized by a monoclonal expansion of predominantly small B-lymphocytes with variable plasmacytoid differentiation.
  • The median survival of patients with LPL or WM is 50-60 months, transformation to large cell lymphoma may occur.
  • Stage definition is irrelevant in WM considering that initiation of therapy is decided on the bases of prognostic factors and the development of disease-related symptoms and signs.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499469.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 120
  •  go-up   go-down


1
Advertisement
4. Meziane M, Hesse S, Chetaille B, Bien-Aimée A, Grob JJ, Richard MA: [Cutaneous large B-cell leg-type lymphoma occurring on a leg burn]. Ann Dermatol Venereol; 2009 Nov;136(11):791-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous large B-cell leg-type lymphoma occurring on a leg burn].
  • We report a case of primary leg-type cutaneous large B-cell lymphoma occurring on the site a previous leg burn.
  • A few rare cases of cutaneous lymphoma forming on burn scars have been described, but these concern primary cutaneous lymphomas of the T-cell phenotype.
  • Histological examination of the skin biopsy revealed the existence in the skin ulcers of atypical large lymphoid cells having an immunoblastic or centroblastic morphology and shown by immunohistochemistry to be of the B-cell phenotype, thereby evoking a diagnosis of large B-cell lymphoma.
  • The lymphoma cells were positive for MUM1/IRF4 and BCL2, and more weakly for BCL6, but negative for CD10.
  • DISCUSSION: This case is novel in that it involves primary large B-cell lymphoma, leg type, occurring on burn scar tissue.
  • Venous insufficiency and lymphatic stasis have already been incriminated in the genesis of this type of lymphoma; the prior injury and resulting immune dysregulation at the burn site may have also contributed to the development of this neoplasia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burns / complications. Lymphoma, B-Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Burns.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917431.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


15. Hernández-Machín B, Fernández-Misa R, Alfonso JL, Maeso MC, Marrero C, Borrego L: [Primary cutaneous diffuse large B-cell lymphoma of the leg according to the new WHO-EORTC classification. Two cases]. Actas Dermosifiliogr; 2005 Nov;96(9):607-11
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cutaneous diffuse large B-cell lymphoma of the leg according to the new WHO-EORTC classification. Two cases].
  • Their clinical behavior is generally indolent, and only occasionally is the development of extracutaneous disease observed.
  • Both the EORTC and the WHO have proposed alternative classifications for these entities, with significant discrepancies that were finally resolved through the development of a new classification (WHO-EORTC classification for cutaneous lymphomas), which standardizes criteria that had previously been different.
  • We present two new cases of primary cutaneous diffuse large B-cell lymphoma of the leg according to the new classification.
  • [MeSH-major] Leg. Lymphoma, B-Cell / classification. Lymphoma, Large B-Cell, Diffuse / classification. Skin Neoplasms / classification

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16476307.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


16. Lossos I, Craig MD, Tallman MS, Boccia RV, Conkling PR, Becerra C, Komarnitsky PB, Hamilton BL, Lewis J, Miller WH: Novel organic arsenic molecule darinaparsin: Development of IV and oral forms. J Clin Oncol; 2009 May 20;27(15_suppl):8501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel organic arsenic molecule darinaparsin: Development of IV and oral forms.
  • Darinaparsin i.v. activity in lymphoma is being evaluated in a phase II study.
  • RESULTS: The phase II study has accrued 28 lymphoma patients (21 non-Hodgkin's, 7 Hodgkin's); median age at baseline 61 years, ECOG ≤2, median number of prior therapies 3.
  • A total of 63 cycles of darinaparsin have been administered to subjects with lymphoma. No Gr.
  • CONCLUSIONS: Darinaparsin is active in heavily pretreated patients with advanced lymphoma and has been very well tolerated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960853.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Cheson BD, Vose JM, Bartlett NL, Lopez A, Van der Jagt RH, Tolcher AW, Weisenburger DD, Seiz AL, Shamsili S, Keating AT: Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL). J Clin Oncol; 2009 May 20;27(15_suppl):8502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL).
  • YM155, a survivin suppressant, has exhibited anti-tumor activity in solid tumors and non-Hodgkins lymphoma (NHL), including DLBCL patients enrolled in Phase I and Phase II monotherapy studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960852.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Blaes A, Peterson BA, Yee D, Virnig B: Do ACE-I protect against the development of doxorubicin cardiac toxicity? J Clin Oncol; 2009 May 20;27(15_suppl):6623

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do ACE-I protect against the development of doxorubicin cardiac toxicity?
  • This retrospective study analyzes whether ACE-I and other medications are protective in the development of DOX cardiomyopathy.
  • Cancer diagnosis was breast (n = 26), lymphoma (n = 92), and other (n = 25).
  • CONCLUSIONS: DOX chemotherapy has been associated with the development of cardiomyopathies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961796.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Regairaz M, Munier F, Sartelet H, Marty V, Castaing M, Michiels S, Fabre M, Roesel J, Vassal G: Role of ALK activation in the development and maintenance of the neoplastic phenotype in neuroblastoma. J Clin Oncol; 2009 May 20;27(15_suppl):10008

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of ALK activation in the development and maintenance of the neoplastic phenotype in neuroblastoma.
  • : 10008 Background: Activating mutations of the Anaplastic Lymphoma Kinase (ALK) receptor could be responsible for most familial neuroblastoma cases and for up to 15% of somatic cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962533.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Ginn SL, Liao SH, Dane AP, Hu M, Hyman J, Finnie JW, Zheng M, Cavazzana-Calvo M, Alexander SI, Thrasher AJ, Alexander IE: Lymphomagenesis in SCID-X1 Mice Following Lentivirus-mediated Phenotype Correction Independent of Insertional Mutagenesis and γc Overexpression. Mol Ther; 2010 May;18(5):965-976

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : The development of leukemia as a consequence of vector-mediated genotoxicity in gene therapy trials for X-linked severe combined immunodeficiency (SCID-X1) has prompted substantial research effort into the design and safety testing of integrating vectors.
  • We observed incomplete or absent T- and B-cell development in mice transplanted with progenitors expressing γc from the phosphoglycerate kinase (PGK) and Wiscott-Aldrich syndrome (WAS) promoters, respectively.
  • In contrast, functional T- and B-cell compartments were restored in mice receiving an equivalent vector containing the elongation factor-1-α (EF1α) promoter; however, 4 of 14 mice reconstituted with this vector subsequently developed lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178557.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Scobie L, Hector RD, Grant L, Bell M, Nielsen AA, Meikle S, Philbey A, Thrasher AJ, Cameron ER, Blyth K, Neil JC: A Novel Model of SCID-X1 Reconstitution Reveals Predisposition to Retrovirus-induced Lymphoma but No Evidence of γC Gene Oncogenicity. Mol Ther; 2009 Jun;17(6):1031-1038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Novel Model of SCID-X1 Reconstitution Reveals Predisposition to Retrovirus-induced Lymphoma but No Evidence of γC Gene Oncogenicity.
  • These mice demonstrated mildly perturbed T-cell development, with an increased proportion of thymic CD8 cells, but showed no predisposition to tumor development even on highly tumor prone backgrounds or after γ-retrovirus infection.
  • The human CD2-γC transgene rescued T and B-cell development in γC<sup>-/-</sup> mice but with an age-related delay, mimicking postnatal reconstitution in SCID-X1 gene therapy subjects.
  • However, an underlying predisposition conferred by the SCID-X1 background appears to collaborate with insertional mutagenesis to increase the risk of tumor development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28182909.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Luong NV, Kantarjian HM, Faderl SH, Thomas DA, Vu KD: Occurence of venothromboembolism (VTE) in patients (pts) with acute lymphocytic leukemia (ALL), Burkitt's leukemia/lymphoma (BL), or lymphoblastic leukemia (LL). J Clin Oncol; 2009 May 20;27(15_suppl):7059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurence of venothromboembolism (VTE) in patients (pts) with acute lymphocytic leukemia (ALL), Burkitt's leukemia/lymphoma (BL), or lymphoblastic leukemia (LL).
  • Although neoplastic diseases are known risk factors for the development of VTE, little is known about the incidence and predisposing factors of VTE among leukemia patients (pts).
  • METHODS: We performed a retrospective study to determine the incidence and risk factors associated with development of VTE among pts with ALL, BL, LL at M. D.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961450.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Ney DE, Reiner AS, Skinner HD, Panageas KS, DeAngelis LM, Abrey LE: Characteristics and outcomes of elderly patients with primary CNS lymphoma (PCNSL). J Clin Oncol; 2009 May 20;27(15_suppl):2070

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcomes of elderly patients with primary CNS lymphoma (PCNSL).
  • Administration of RT was associated with the development of neurotoxicity (p < 0.0001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964697.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Karimi P, Shokri A, Etemadi L, Negar Rezania N: Factors affecting the hematological and nonhematological toxicities in B-cell lymphoma patients during treatment. J Clin Oncol; 2009 May 20;27(15_suppl):e18004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting the hematological and nonhematological toxicities in B-cell lymphoma patients during treatment.
  • : e18004 Background: Despite recent improvements, toxicities in B-cell lymphoma patients during treatment remains a major challenge for leukemia community.
  • The aim of this study was to determine factors affecting the hematological and non-hematological toxicities in B-cell lymphoma patients during treatment.
  • METHODS: This multicentral cross-sectional study was performed on 68 diagnosed B-cell lymphoma patients (17-72 y/o, mean age 53y/o) admitted in three cancer centers for treatment during 2003-2008.
  • Furthermore, being female was significantly associated with the development of grade 3 or 4 neutropenia [17/49 (35%) versus 8/53 (15%), p = 0.003].
  • CONCLUSIONS: Multivariate analysis demonstrate that some factors like female gender, BM involvement, and serum LDH level could be useful for predicting the hematological and nonhematological toxicities in B-cell lymphoma patients during treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964008.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Sonnichsen D, Liao S, Berkenblit A, Boni J: Population pharmacokinetic modeling for intravenous temsirolimus and sirolimus metabolite in subjects with various solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2522

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2522 Background: Temsirolimus (TEMSR) is an mTOR inhibitor approved for treatment of patients with advanced renal cell carcinoma, and under development for relapsed/refractory mantle cell lymphoma (MCL).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961845.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Milani C, Castillo J: HIV-associated peripheral T-cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated peripheral T-cell lymphoma.
  • Data regarding patient age, gender, HIV status (CD4 count, viral load, opportunistic infections), use of HAART, lymphoma features (B symptoms, stage, sites of involvement, immunophenotype, molecular studies), EBV coinfection, therapy, and outcome (survival, cause of death) were analyzed and reported descriptively.
  • Twenty-two patients (69%) died complicated by infections in 57% and lymphoma progression in 36% of cases.
  • The role of HAART and EBV in the development of PTCL needs further clarification.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961094.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Acosta M, Duvic M, Lopez-Anaya A: Relationship between efficacy of denileukin diftitox (Dd) and antibody development in cutaneous T-cell lymphoma (CTCL): An analysis of two phase III studies. J Clin Oncol; 2009 May 20;27(15_suppl):e19534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between efficacy of denileukin diftitox (Dd) and antibody development in cutaneous T-cell lymphoma (CTCL): An analysis of two phase III studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961028.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Eckardt JR, Ku N, DeMaggio A, Reese M, Levonyak M, Jain V: Impact of direct physician-to-physician contact on accelerating oncology clinical trial accrual. J Clin Oncol; 2009 May 20;27(15_suppl):6613

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 6613 Background: The development of more effective oncology agents is critically dependent on the completion of clinical trials; currently, >4000 oncology trials listed in www.clinicaltrials.gov are accruing pts in the US.
  • From Feb 2008 to December 2008, we implemented this strategy to increase accrual to 5 oncology trials (2 placebo controlled randomized trials and 3 phase II trials in breast cancer, non-Hodgkin's lymphoma and soft tissue sarcoma).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961766.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Takahashi S, Kosaka T, Hattori M, Fujimoto-Ouchi K, Shimonaka Y, Yasuno H, Noguchi M, Mori K, Ogata E: Cancer-related anemia: Correlation analysis among serum levels of hemoglobin, IL-6, hepcidin, albumin, and erythropoietin. J Clin Oncol; 2009 May 20;27(15_suppl):e20655

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Anemia in newly diagnosed patients (pts) with solid tumors or malignant lymphoma was studied excluding pts showing evidence of myelosuppression and hepatic and renal failure.
  • A rat anti-mouse IL-6 receptor monoclonal antibody prevented the development of anemia in the LC-6-JCK model.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961624.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Jakó J, Szerafin L, Nagy P: [Second cancers in hematologic malignancies (epidemiologic observations from a 20-year period)]. Orv Hetil; 2005 Mar 6;146(10):461-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Szekunder carcinomák malignus hematológiai betegségekben (a Szabolcs-Szatmár-Bereg megyei leukaemia/lymphoma regiszter 1983-2002 közötti adatainak elemzése).
  • Prior reports indicate that patients with some hematologic malignancies (for example chronic lymphocytic leukemia, non-Hodgkin's lymphoma) may be at increased risk of second neoplasms.
  • The age of patients with second cancers seemed to be not too important, but it was of crucial importance in patients with Hodgkin's disease and non-Hodgkin's lymphoma.
  • The role of immunodeficiency in the development of second cancers may be important in patients with Hodgkin's disease, non-Hodgkin's lymphoma and chronic lymphocytic leukemia (the number of second cancers in their patients with multiple myeloma and hairy cell leukemia was too small do draw a conclusion).
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Female. Hodgkin Disease / epidemiology. Hodgkin Disease / immunology. Humans. Hungary / epidemiology. Immunocompromised Host. Leukemia / epidemiology. Lymphoma / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / immunology. Male. Middle Aged. Registries. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15835344.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


31. Jardin F: Development of autoimmunity in lymphoma. Expert Rev Clin Immunol; 2008 Mar;4(2):247-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of autoimmunity in lymphoma.
  • Development of lymphoproliferative diseases during the course of autoimmune and chronic inflammatory conditions is well established.
  • Conversely, development of clinical or biological signs of autoimmunity at the time of the diagnosis of lymphoma or during its course indicates that lymphoma and autoimmune manifestations may constitute two faces of the same process.
  • The aim of this review is to describe autoimmune manifestations related to non-Hodgkin's lymphoma and Hodgkin's lymphoma, their specificity according to the lymphoma subtype and their physiopathological signification.
  • Lymphoma-related autoimmune manifestations include mainly skin diseases, hematological manifestations, rheumatic diseases and renal lesions.
  • Despite the lack of studies providing a systematic prospective assessment, autoimmune manifestations are observed in all lymphoma subtypes and seem particularly prevalent in marginal-zone lymphoma and T-cell lymphoma.
  • Monoclonal antibodies (including rituximab, Campath-1H or epratuzumab) constitute the most promising approach to treat lymphoma-related immune disorders.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20477054.001).
  • [ISSN] 1744-8409
  • [Journal-full-title] Expert review of clinical immunology
  • [ISO-abbreviation] Expert Rev Clin Immunol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Briones J: Emerging therapies for B-cell non-Hodgkin lymphoma. Expert Rev Anticancer Ther; 2009 Sep;9(9):1305-16
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging therapies for B-cell non-Hodgkin lymphoma.
  • In recent years considerable progress has been made in the treatment of patients with B-cell non-Hodgkin lymphoma (NHL).
  • In recent years, the knowledge of the cellular and molecular biology of distinct types of B-cell NHL have led to the development of a new class of drugs that specifically targets unique disease-specific pathways.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Delivery Systems. Lymphoma, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19761434.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents
  • [Number-of-references] 107
  •  go-up   go-down


33. Haines BB, Ryu CJ, Chen J: Recombination activating genes (RAG) in lymphoma development. Cell Cycle; 2006 May;5(9):913-6
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recombination activating genes (RAG) in lymphoma development.
  • Mechanisms by which RAG can provoke or perpetuate lymphoma include deregulation of certain genes by translocation to antigen receptor regulatory regions, the formation of chimeric oncogenes, inactivation of tumor suppressor or micro-RNA loci, or activation of oncogenes.
  • Here we present the T cell receptor enhancer (Ebeta) deficient mouse as a tractable in vivo model system to study the role of RAG activity in the context of lymphoma development, and contrast our system with those of others.
  • We posit a general hypothesis that virtually any mutation that impairs early lymphocyte development at stages when RAG is expressed can constitute a pro-carcinogenic event.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16687916.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Rag2 protein, mouse
  •  go-up   go-down


34. Benouaich-Amiel A, Kaloshi G, Khe HX: [Primitif cerebral lymphoma]. Rev Prat; 2006 Oct 31;56(16):1787-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primitif cerebral lymphoma].
  • Primitif cerebral lymphoma is a rare disease but has increased in incidence over the past decades.
  • An ocular lymphoma (uveitis) is frequently associated.
  • Immunodeficiency is a contributing factor to the development of primitive cerebral lymphoma; in this setting, differentiating them from infectious lesions (toxoplasmosis in particular) may be difficult.
  • [MeSH-major] Brain Neoplasms. Lymphoma

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17315504.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 19
  •  go-up   go-down


35. Borchmann P, Schnell R, Engert A: Immunotherapy of Hodgkin's lymphoma. Eur J Haematol Suppl; 2005 Jul;(66):159-65
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy of Hodgkin's lymphoma.
  • Many new treatment approaches have given promising results in experimental Hodgkin's lymphoma (HL) models.
  • Another rationale for the development of these immunotherapies is to eliminate residual disease and thereby to prevent relapses from the disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007886.001).
  • [ISSN] 0902-4506
  • [Journal-full-title] European journal of haematology. Supplementum
  • [ISO-abbreviation] Eur J Haematol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Immunotoxins
  • [Number-of-references] 60
  •  go-up   go-down


36. Blyth K, Slater N, Hanlon L, Bell M, Mackay N, Stewart M, Neil JC, Cameron ER: Runx1 promotes B-cell survival and lymphoma development. Blood Cells Mol Dis; 2009 Jul-Aug;43(1):12-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Runx1 promotes B-cell survival and lymphoma development.
  • Runx1 is essential for the homeostatic control of normal hematopoiesis and is required for lymphoid development.
  • [MeSH-major] B-Lymphocytes / pathology. Core Binding Factor Alpha 2 Subunit / genetics. Core Binding Factor Alpha 2 Subunit / metabolism. Lymphoma / genetics. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269865.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Runx1 protein, mouse
  •  go-up   go-down


37. Perrett CM, Harwood CA, Khorshid M, Cerio R, McGregor JM: Primary cutaneous B-cell lymphoma associated with actinic prurigo. Br J Dermatol; 2005 Jul;153(1):186-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous B-cell lymphoma associated with actinic prurigo.
  • We describe two patients with a diagnosis of actinic prurigo who subsequently developed cutaneous B-cell lymphoma.
  • We propose that chronic antigenic stimulation by ultraviolet radiation, in the context of actinic prurigo, may have been causal in the development of these unusual lymphomas.
  • [MeSH-major] Lymphoma, B-Cell / etiology. Photosensitivity Disorders / complications. Prurigo / complications. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029348.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Piña-Oviedo S, Ortiz-Hidalgo C: [Historical development and current concepts on B-cell lymphomas of the marginal extraganglionar site of lymphoid tissue associated with MALT lymphoma. A tribute to Dennis H Wright and Peter G Isaacson]. Gac Med Mex; 2007 May-Jun;143(3):237-44
Genetic Alliance. consumer health - B-Cell Lymphomas.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Historical development and current concepts on B-cell lymphomas of the marginal extraganglionar site of lymphoid tissue associated with MALT lymphoma. A tribute to Dennis H Wright and Peter G Isaacson].
  • Significant advances in the understanding of marginal zone lymphoma since the first description in 1983 by Peter Isaacson and Dennis Wright have been noted.
  • Eradication of H. pylori produces a clinical regression of the lymphoma in about 75% of cases.
  • The histological hallmarks of MALT lymphoma include neoplastic centrocyte-like B cells, cells resembling monocytoid cells and the presence of lymphoepithelial lesions.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / history

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722452.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] Biography; English Abstract; Historical Article; Journal Article; Portraits
  • [Publication-country] Mexico
  • [Personal-name-as-subject] Wright DH; Isaacson PG
  •  go-up   go-down


39. Link BK: Imaging guiding therapy development in lymphoma. Clin Pharmacol Ther; 2008 Oct;84(4):443-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging guiding therapy development in lymphoma.
  • Radiographic imaging has deep roots as a surrogate for efficacy in guiding decisions in therapy development in lymphoma.
  • New therapies in lymphoma are still required to induce radiographic response to be considered useful in a paradigm dating back at least to chest roentgenograms and Hodgkin's lymphoma (HL).
  • This paradigm will soon be challenged by new therapeutic strategies under development, but creative imaging approaches can still guide such development.
  • [MeSH-major] Lymphoma / radiography. Lymphoma / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18802425.001).
  • [ISSN] 0009-9236
  • [Journal-full-title] Clinical pharmacology and therapeutics
  • [ISO-abbreviation] Clin. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals
  • [Number-of-references] 12
  •  go-up   go-down


40. Smith TJ, Yamamoto K, Kurata M, Yukimori A, Suzuki S, Umeda S, Sugawara E, Kojima Y, Sawabe M, Nakagawa Y, Suzuki K, Crawley JT, Kitagawa M: Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma. Exp Mol Pathol; 2010 Dec;89(3):284-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma.
  • Thus, frozen samples of 51 lymph nodes from patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL) were analyzed for the expression of TLR1 to 9 using quantitative real-time PCR, and compared to those in reactive lymphadenopathy (RL) samples.
  • Although TLR5 showed lower expression in FL, expression of TLR3, TLR6, TLR7 and TLR9 did not vary significantly between different lymphoma subtypes.
  • Double immunostaining revealed an increase in the number of TLR2 and/or TLR8 expressing lymphoma cells in DLBCL.
  • TLR expression is highly variable among lymphoma subtypes.
  • However, despite this some significant differences exist that may prove useful in the development of novel therapeutic strategies.
  • [MeSH-major] Lymphoma, Follicular / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, T-Cell / metabolism. Toll-Like Receptors / biosynthesis


41. Meredith RF, Knox SJ: Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2006;66(2 Suppl):S15-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
  • Food and Drug Administration for the treatment of patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), and clinical trials have shown that they are effective as monotherapies in the salvage setting, producing response rates that are often higher and durations of response that are often longer than those with chemotherapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979433.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Iodine Radioisotopes; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 0 / iodine-131 anti-B1 antibody
  • [Number-of-references] 45
  •  go-up   go-down


42. Arai H, Iso H, Arai Y, Tadokoro J, Nakamura Y, Yamagata T, Mitani K: [Mediastinal large B-cell lymphoma associated with systemic sclerosis]. Rinsho Ketsueki; 2009 Feb;50(2):97-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mediastinal large B-cell lymphoma associated with systemic sclerosis].
  • Malignant lymphoma (ML) is frequently associated with several forms of collagen diseases such as Sjören syndrome, systemic lupus erythematodes, and rheumatoid arthritis.
  • Here we report an SSc patient who developed mediastinal (thymic) large B-cell lymphoma (MLBCL).
  • The patient was treated with 6 courses of CHOP regimen, resulting in complete remission of lymphoma.
  • Our case suggests that intensive monitoring for the development of ML is needed in newly diagnosed SSc patients.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / etiology. Scleroderma, Systemic / complications. Thymus Neoplasms / etiology

  • Genetic Alliance. consumer health - Diffuse Scleroderma.
  • MedlinePlus Health Information. consumer health - Scleroderma.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19265302.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


43. Lossos IS, Morgensztern D: Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol; 2006 Feb 20;24(6):995-1007
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic biomarkers in diffuse large B-cell lymphoma.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma.
  • The recent application of DNA microarrays and tissue array technologies allowed a better understanding of the biology of lymphoma and the development of novel diagnostic tools capable of improving the current models for outcome prediction.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lymphoma, B-Cell / chemistry. Lymphoma, Large B-Cell, Diffuse / chemistry

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418498.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109335
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 134
  •  go-up   go-down


44. Morgensztern D, Lossos IS: Molecular prognostic factors in diffuse large B-cell lymphoma. Curr Treat Options Oncol; 2005 Jul;6(4):269-77
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular prognostic factors in diffuse large B-cell lymphoma.
  • The treatment of patients with diffuse large B-cell lymphoma (DLBCL) has been guided traditionally by clinical parameters such as the Ann Arbor Staging Classification for Hodgkin's disease.
  • Use of DNA microarray, real-time reverse transcription polymerase chain reaction, and tissue array immunohistochemistry methodologies makes the development of new classifications possible based on molecular profiling.
  • [MeSH-major] Biomarkers, Tumor / analysis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1861-74 [11748286.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10209-13 [10954754.001]
  • [Cites] Nat Genet. 1999 Jan;21(1 Suppl):5-9 [9915493.001]
  • [Cites] Blood. 1989 Aug 1;74(2):551-7 [2752132.001]
  • [Cites] Blood. 2000 Mar 15;95(6):1900-10 [10706853.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1460-6 [8123837.001]
  • [Cites] Ann Oncol. 1992 Nov;3(9):711-7 [1450060.001]
  • [Cites] Am J Pathol. 2004 Feb;164(2):613-22 [14742266.001]
  • [Cites] Nat Genet. 1997 Jun;16(2):161-70 [9171827.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Blood. 1997 Jul 1;90(1):244-51 [9207459.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1108-15 [12176791.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):467-74 [12598355.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4279-84 [12576316.001]
  • [Cites] Leukemia. 1990 May;4(5):383-9 [2201831.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):582-8 [11293907.001]
  • [Cites] Histopathology. 2001 Aug;39(2):156-62 [11493332.001]
  • [Cites] Blood. 1988 Apr;71(4):1157-60 [3281723.001]
  • [Cites] Blood. 1996 Jan 1;87(1):265-72 [8547651.001]
  • [Cites] N Engl J Med. 2004 Apr 29;350(18):1828-37 [15115829.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2924-32 [15591113.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2131-8 [8683246.001]
  • [Cites] Nat Rev Drug Discov. 2002 Dec;1(12):951-60 [12461517.001]
  • [Cites] J Clin Oncol. 1986 Jun;4(6):859-65 [2423653.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):414-9 [15085385.001]
  • [Cites] Ann Intern Med. 1986 Jun;104(6):757-65 [2422995.001]
  • [Cites] Blood. 1994 May 1;83(9):2423-7 [8167331.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Nov;82(21):7439-43 [2865728.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1046-51 [8704213.001]
  • [Cites] Semin Immunol. 1991 Nov;3(6):379-90 [1799668.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):545-51 [15517363.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Cancer Treat Rep. 1977 Sep;61(6):1023-7 [902260.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):35-40 [9440720.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2767-75 [12767089.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3152-62 [9787151.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1518-27 [2674337.001]
  • [Cites] Drug Discov Today. 2001 Oct 15;6(20):1062-1067 [11590035.001]
  • [Cites] Blood. 2003 Jan 15;101(2):433-40 [12509382.001]
  • [Cites] Immunol Today. 1989 Dec;10(12):423-8 [2695102.001]
  • [Cites] Immunol Rev. 1986 Jun;91:39-60 [2426181.001]
  • [Cites] J Clin Oncol. 1991 Feb;9(2):211-9 [1703226.001]
  • [Cites] Am J Hematol. 2003 Jun;73(2):101-7 [12749011.001]
  • [Cites] N Engl J Med. 1994 Jul 14;331(2):74-80 [8208268.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3712-8 [11090051.001]
  • [Cites] Blood. 2005 May 15;105(10):3979-86 [15677569.001]
  • [Cites] Cancer. 2000 Sep 15;89(6):1387-95 [11002235.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] N Engl J Med. 1997 Aug 21;337(8):529-34 [9262496.001]
  • [Cites] Cell. 1985 Jul;41(3):899-906 [3924412.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Blood. 2003 Jan 1;101(1):78-84 [12393466.001]
  • [Cites] Blood. 2001 Aug 15;98(4):945-51 [11493437.001]
  • (PMID = 15967080.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109335
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 58
  •  go-up   go-down


45. Küppers R: The biology of Hodgkin's lymphoma. Nat Rev Cancer; 2009 Jan;9(1):15-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The biology of Hodgkin's lymphoma.
  • Hodgkin's lymphoma was first described in 1832.
  • The aetiology of this lymphoma, however, remained enigmatic for a long time.
  • HRS cells in classical Hodgkin's lymphoma have several characteristics that are unusual for lymphoid tumour cells, and the Hodgkin's lymphoma microenvironment is dominated by an extensive mixed, potentially inflammatory cellular infiltrate.
  • Understanding the contribution of all of these changes to the pathogenesis of this disease is essential for the development of novel therapies.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19078975.001).
  • [ISSN] 1474-1768
  • [Journal-full-title] Nature reviews. Cancer
  • [ISO-abbreviation] Nat. Rev. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / Transcription Factors; 0 / Viral Proteins
  • [Number-of-references] 164
  •  go-up   go-down


46. Okamoto R: [Malignant lymphoma]. Gan To Kagaku Ryoho; 2009 Dec;36(13):2532-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant lymphoma].
  • FDG-PET has technical limitations, variability of FDG avidity among different lymphoma histologic subtypes, and in a large number of etiologies shows false-negative and false positive results.
  • Most studies of FDG-PET involve patients with Hodgkin's disease or diffuse large B-cell lymphoma.
  • FDG PET in lymphoma is being incorporated into the response assessment in lymphoma as published by the Imaging Subcommittee of International Harmonization Project in Lymphoma.
  • New guidelines, the Revised Response Criteria for Malignant Lymphoma, are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma.
  • PET as a biomarker has the potential to change the current model of drug development.
  • [MeSH-major] Lymphoma / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009452.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


47. Mori T: [Malignant lymphoma]. Gan To Kagaku Ryoho; 2007 Feb;34(2):162-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant lymphoma].
  • Based on the systematic improvements in treatment over recent decades, more than 70% of children and adolescents with non-Hodgkin lymphoma will survive at least 5 years with standard chemotherapy.
  • This report highlights several advances in treatment for each histologic subtype of childhood non-Hodgkin lymphoma, focusing on published results of clinical trials from European and North American study groups.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Child. Clinical Trials as Topic. Combined Modality Therapy. Drug Administration Schedule. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301521.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 25
  •  go-up   go-down


48. Hoefnagel JJ, Mulder MM, Dreef E, Jansen PM, Pals ST, Meijer CJ, Willemze R, Vermeer MH: Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma. Mod Pathol; 2006 Sep;19(9):1270-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma.
  • Expression patterns of eight transcription factors involved in different stages of B-cell development were investigated in a large group of primary cutaneous B-cell lymphomas and compared with expression patterns during normal B-cell development.
  • Primary cutaneous marginal zone B-cell lymphoma showed expression of Pax-5, PU.1, Oct2 and BOB.1, but not Bcl-6 by the neoplastic B-cells, and Mum1/IRF4 and Blimp-1 by the neoplastic plasma cells.
  • In conclusion, in primary cutaneous follicle center lymphoma and primary cutaneous marginal zone B-cell lymphoma expression patterns were observed similar to their supposed benign counterparts, germinal center B-cells and postgerminal center B-cells, respectively, which might reflect their indolent clinical behaviour and excellent prognosis.
  • In contrast, the activated B-cell expression pattern in the group of primary cutaneous large B-cell lymphoma, leg type may contribute to its poor prognosis and Mum1/IRF4 and FOXP1 may serve as additional diagnostic markers for this type of primary cutaneous B-cell lymphoma.
  • [MeSH-major] B-Lymphocytes / metabolism. Lymphoma, B-Cell / metabolism. Skin Neoplasms / metabolism. Transcription Factors / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published online 16 June 2006.
  • (PMID = 16778825.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / FOXP1 protein, human; 0 / Forkhead Transcription Factors; 0 / Interferon Regulatory Factors; 0 / Octamer Transcription Factor-2; 0 / PAX5 protein, human; 0 / POU2AF1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; 0 / Trans-Activators; 0 / Transcription Factors; 0 / interferon regulatory factor-4; 0 / proto-oncogene protein Spi-1
  •  go-up   go-down


49. Magrath I: Denis Burkitt and the African lymphoma. Ecancermedicalscience; 2009;3:159

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Denis Burkitt and the African lymphoma.
  • Burkitt lymphoma has provided a model for the understanding of the epidemiology, the molecular abnormalities that induce tumours, and the treatment of other lymphomas.
  • In addition, it is time to re-explore, with modern techniques, some of the questions that were raised some 50 years ago shortly after Burkitt's first description, as well as new questions that can be asked only in the light of modern understanding of the immune system and the molecular basis of tumor development.
  • The African lymphoma has taught us much, but there is a great deal still to be learned.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22276020.001).
  • [ISSN] 1754-6605
  • [Journal-full-title] Ecancermedicalscience
  • [ISO-abbreviation] Ecancermedicalscience
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3224008
  •  go-up   go-down


50. Kato I, Manabe A, Aoyama C, Kamiya T, Morimoto T, Matsufuji H, Suzuki K, Kitagawa Y, Hori T, Tsurusawa M, Kiyokawa N, Junichiro F, Hosoya R: Development of diffuse large B cell lymphoma during the maintenance therapy for B-lineage acute lymphoblastic leukemia. Pediatr Blood Cancer; 2007 Feb;48(2):230-2
Genetic Alliance. consumer health - Lymphoblastic lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of diffuse large B cell lymphoma during the maintenance therapy for B-lineage acute lymphoblastic leukemia.
  • Non-Hodgkin lymphoma (NHL) is a very rare complication of acute lymphoblastic leukemia (ALL).
  • While he was receiving maintenance treatment 2 years and 9 months after the diagnosis of ALL, diffuse large B cell lymphoma (DLBL) was diagnosed from a biopsy of an abdominal mass.
  • The patient has been free from the recurrence of ALL or DLBL for 16 months after the development of DLBL.
  • [MeSH-major] Lymphoma, B-Cell / etiology. Lymphoma, Large B-Cell, Diffuse / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications


51. Vitolo U, Ferreri AJ, Zucca E: Primary testicular lymphoma. Crit Rev Oncol Hematol; 2008 Feb;65(2):183-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular lymphoma.
  • Primary non-Hodgkin's lymphoma of the testis (PTL) accounts for about 9% of testicular neoplasms and 1-2% of all non-Hodgkin's lymphomas.
  • Anecdotal reports associated PTL development with trauma, chronic orchitis, cryptorchidism, or filariasis exist, but no case-control studies have confirmed their etiologic significance.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common histotype in primary forms; aggressive histologies, especially Burkitt's lymphoma, are prevalent in cases of secondary involvement of testis.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Testicular Neoplasms

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962036.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 40
  •  go-up   go-down


52. Iwano M, Watanabe N, Matsushima Y, Seno H, Oki K, Sakurai T, Inagaki H, Okazaki K, Chiba T: Rapid development of diffuse large B-Cell lymphoma after successful eradication of Helicobacter pylori for gastric MALT lymphoma. Am J Gastroenterol; 2006 Dec;101(12):2878-83
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid development of diffuse large B-Cell lymphoma after successful eradication of Helicobacter pylori for gastric MALT lymphoma.
  • Primary low-grade mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach has a potential to transform to high-grade diffuse large B-cell lymphoma (DLBCL).
  • However, the clonal relation between MALT lymphoma and de novo DLBCL is still controversial.
  • We report here three patients with Helicobacter pylori (H. pylori)-positive gastric MALT lymphoma rapidly progressing to DLBCL at the same site after successful eradication of H. pylori.
  • Although MALT lymphomas in our cases did not possess t(11; 18)(q21;q21), sequence analysis of the rearranged immunoglobulin heavy chain gene showed no clonal relation between preceding MALT lymphoma cells and de novo DLBCL cells at the same site.
  • These findings question the scenario of direct clonal progression of low-grade MALT lymphomas without t(11; 18)(q21;q21) to DLBCL and serve as a reminder of the risk of the progression of DLBCL with a distinct clonality immediately after H. pylori eradication for low-grade MALT lymphoma.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Helicobacter Infections / drug therapy. Helicobacter pylori. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Stomach Neoplasms / pathology


53. Herbertson R, Hancock BW: Hodgkin Lymphoma in adolescents. Cancer Treat Rev; 2005 Aug;31(5):339-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin Lymphoma in adolescents.
  • With the development of an integrated treatment approach, the cure rate and survival of patients with Hodgkin Lymphoma (HL) is now high.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951118.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 131
  •  go-up   go-down


54. Weniger MA, Barth TF, Möller P: Genomic alterations in Hodgkin's lymphoma. Int J Hematol; 2006 Jun;83(5):379-84
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic alterations in Hodgkin's lymphoma.
  • Cytogenetic analysis of Hodgkin's lymphoma (HL) is hampered by the scarcity of neoplastic cells within a sea of reactive cells.
  • In this article, we review genomic aberrations that may contribute to the development and maintenance of the morphologic and clinical presentation of these beta-cell lymphoma entities.
  • [MeSH-minor] Chromosomes, Human, Pair 2 / genetics. Chromosomes, Human, Pair 9 / genetics. Humans. Lymphoma, B-Cell / genetics. Nucleic Acid Hybridization / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S4-11 [16341240.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4283-97 [12036854.001]
  • [Cites] J Clin Pathol. 2002 Mar;55(3):162-76 [11896065.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Oct;38(2):126-36 [12939740.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):211-5 [15551733.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):549-52 [10676635.001]
  • [Cites] Oncogene. 2004 Feb 12;23(6):1326-31 [14961078.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1404-13 [16206268.001]
  • [Cites] Nat Immunol. 2004 Sep;5(9):875-6 [15334080.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):352-6 [16049307.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3326-34 [15284123.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1474-7 [11830502.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Aug;31(4):316-25 [11433522.001]
  • [Cites] Cancer Cell. 2002 Jul;2(1):9-15 [12150820.001]
  • [Cites] Blood. 2001 Jan 15;97(2):496-501 [11154228.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2351-7 [14645011.001]
  • [Cites] Blood. 2000 Aug 1;96(3):808-22 [10910891.001]
  • [Cites] Semin Cancer Biol. 2005 Feb;15(1):25-32 [15613285.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):871-4 [16357870.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):678-82 [11340571.001]
  • [Cites] Blood Rev. 2006 Jan;20(1):1-13 [16426940.001]
  • [Cites] Blood. 2004 Jun 15;103(12 ):4630-5 [14976049.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):363-71 [10830743.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):593-606 [16077907.001]
  • [Cites] Int J Cancer. 2005 May 10;114(6):909-16 [15645496.001]
  • [Cites] Blood. 2003 Jan 15;101(2):706-10 [12393409.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 May;6(5):376-85 [15852042.001]
  • [Cites] Blood. 2002 Jan 15;99(2):618-26 [11781246.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):1007-13 [12213729.001]
  • [Cites] Oncogene. 2005 Dec 15;24(56):8259-67 [16091734.001]
  • [Cites] Blood. 2005 May 15;105(10):4051-9 [15677564.001]
  • [Cites] Cell Immunol. 2001 Jul 10;211(1):37-42 [11585386.001]
  • [Cites] Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R93-R100 [15809278.001]
  • [Cites] J Med Genet. 2005 Jul;42(7):595-601 [15994882.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Apr;30(4):393-401 [11241792.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4553-60 [15728122.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2214-9 [14523479.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1845-53 [11238128.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2679-84 [16532038.001]
  • [Cites] J Pathol. 2005 Oct;207(2):243-9 [16041695.001]
  • [Cites] Blood. 1999 Dec 15;94(12):3997-4010 [10590043.001]
  • [Cites] Int J Hematol. 2001 Aug;74(2):178-85 [11594519.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1220-35 [12393483.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1411-21 [16224207.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):5002-7 [15047891.001]
  • [Cites] Adv Cancer Res. 2002;84:277-312 [11883530.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Dec;23(4):323-7 [9824205.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2493-500 [16304050.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3509-12 [15867338.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1824-30 [16094416.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5580-94 [11607811.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):45-52 [16007868.001]
  • [Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1381-7 [11830490.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:52-6 [12078904.001]
  • [Cites] Semin Cancer Biol. 2005 Feb;15(1):33-42 [15613286.001]
  • [Cites] Cell Biol Int. 2005 May;29(5):375-83 [15996491.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):196-203 [15644776.001]
  • [Cites] Br J Haematol. 2001 Mar;112(3):768-75 [11260082.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3974-85 [9731511.001]
  • [Cites] Blood. 1996 Sep 1;88(5):1771-9 [8781434.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):251-62 [15803153.001]
  • [Cites] Curr Opin Oncol. 2004 Jan;16(1):25-31 [14685089.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6379-86 [16155023.001]
  • [Cites] Hematology. 2005 Apr;10(2):115-29 [16019457.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1571-8 [8608249.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2207-13 [14523473.001]
  • [Cites] Nat Immunol. 2005 Oct;6(10):1054-60 [16142238.001]
  • [Cites] Nat Immunol. 2003 Jun;4(6):525-32 [12717432.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):29-35 [12507887.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2606-9 [12750286.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3413-20 [11719382.001]
  • [Cites] Leukemia. 2004 Feb;18(2):356-8 [14614518.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):207-12 [10637266.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):540-50 [15229479.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):489-95 [12478664.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2565-74 [16331255.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1941-4 [16287070.001]
  • [Cites] Haematologica. 1999 Apr;84(4):298-305 [10190942.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):205-10 [11774265.001]
  • [Cites] Cell Signal. 2006 Apr;18(4):449-55 [15967637.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):873-81 [14982841.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2866-74 [9531597.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:19-22 [12078897.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):439-47 [15695385.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] Nat Rev Immunol. 2003 Nov;3(11):900-11 [14668806.001]
  • [Cites] Leukemia. 2002 May;16(5):937-9 [11986957.001]
  • [Cites] Histol Histopathol. 2004 Apr;19(2):637-50 [15024721.001]
  • [Cites] Histopathology. 2001 Apr;38(4):368-75 [11318902.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2535-42 [15572583.001]
  • [Cites] Blood. 2003 May 1;101(9):3681-6 [12511414.001]
  • (PMID = 16787866.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 94
  •  go-up   go-down


55. Bibas M, Antinori A: EBV and HIV-Related Lymphoma. Mediterr J Hematol Infect Dis; 2009;1(2):e2009032

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV and HIV-Related Lymphoma.
  • The overall prevalence of HIV-associated lymphoma is significantly higher compared to that of the general population and it continues to be relevant even after the wide availability of highly active antiretroviral therapy (HAART) (1).
  • It has been largely implicated in the development of B-cell lymphoproliferative disorders as Burkitt lymphoma (BL), Hodgkin disease (HD), systemic non Hodgkin lymphoma (NHL), primary central nervous system lymphoma (PCNSL), nasopharyngeal carcinoma (NC).
  • Detailed understanding of the EBV lifecycle and related cancers at the molecular level is required for novel strategies of molecular-targeted cancer chemotherapy The linkage of HIV-related lymphoma with EBV infection of the tumor clone has several pathogenetic, prognostic and possibly therapeutic implications which are reviewed herein.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1999 Jun;26(3):346-56 [10375091.001]
  • [Cites] Blood. 2001 Jul 1;98(1):146-55 [11418474.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2339-44 [11588028.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1731-41 [11748275.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] Nat Med. 2002 Apr;8(4):319-23 [11927927.001]
  • [Cites] AIDS. 2002 May 24;16(8):1195-6 [12004285.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2321-7 [12406882.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15572-7 [12434018.001]
  • [Cites] Lancet. 2003 Jan 18;361(9353):217-23 [12547545.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2982-9 [12782607.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4166-78 [12907455.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5108-21 [12910248.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10399-404 [12925741.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):803-21 [14871955.001]
  • [Cites] Am J Clin Pathol. 2004 May;121(5):727-38 [15151213.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]
  • [Cites] J Pathol. 2008 Sep;216(1):83-92 [18566961.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):763-4 [18756546.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]
  • [Cites] J Exp Med. 1986 Dec 1;164(6):2049-60 [3491176.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):549-60 [7845680.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] J Clin Oncol. 1993 Sep;11(9):1674-81 [8394878.001]
  • [Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7635-9 [1652756.001]
  • [Cites] Lancet. 1991 Oct 19;338(8773):969-73 [1681341.001]
  • [Cites] J Exp Med. 1991 Jan 1;173(1):147-58 [1845872.001]
  • [Cites] Blood. 1989 Feb 15;73(3):792-9 [2537119.001]
  • [Cites] Am J Hematol. 1989 Nov;32(3):200-4 [2816914.001]
  • [Cites] Cell. 1985 Dec;43(3 Pt 2):831-40 [3000618.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1758-67 [7541452.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1072-85 [8214003.001]
  • [Cites] J Virol. 1996 Feb;70(2):1143-53 [8551575.001]
  • [Cites] AIDS. 1996 Aug;10(9):951-8 [8853727.001]
  • [Cites] Curr Opin Oncol. 1996 Sep;8(5):373-6 [9026061.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):16-23 [9892104.001]
  • [Cites] BMJ. 1999 Jul 3;319(7201):23-4 [10390454.001]
  • [Cites] Neurology. 2000 Feb 22;54(4):993-7 [10691003.001]
  • [Cites] Arch Pathol Lab Med. 2001 Feb;125(2):282-5 [11175653.001]
  • [Cites] AJNR Am J Neuroradiol. 1997 Mar;18(3):563-72 [9090424.001]
  • [Cites] J Clin Invest. 1997 Apr 1;99(7):1525-33 [9119996.001]
  • [Cites] Am J Surg Pathol. 1997 Jun;21(6):719-24 [9199651.001]
  • [Cites] J Clin Pathol. 1997 Nov;50(11):911-8 [9462239.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):623-30 [9502401.001]
  • [Cites] Haematologica. 1998 Jan;83(1):87-9 [9542326.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Am J Hematol. 2004 Nov;77(3):291-5 [15495247.001]
  • [Cites] AIDS. 2002 Oct 18;16(15):2001-11 [12370498.001]
  • [Cites] AIDS. 2003 Jan 3;17(1):81-7 [12478072.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):188-92 [12610094.001]
  • [Cites] Histopathology. 2003 Jun;42(6):605-9 [12786898.001]
  • [Cites] Am J Hematol. 2003 Jul;73(3):143-8 [12827649.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):300-9 [12872349.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1768-74 [1373087.001]
  • [Cites] Am J Hematol. 2004 May;76(1):88-91 [15114607.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Neurology. 1997 Mar;48(3):687-94 [9065549.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Presse Med. 2004 Dec 4;33(21):1487-92 [15637794.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4339-44 [16076866.001]
  • [Cites] Clin Infect Dis. 2005 Oct 15;41(8):e76-9 [16163622.001]
  • [Cites] Hematol Oncol. 2005 Jun;23(2):61-7 [16216037.001]
  • [Cites] J Pathol. 2006 Jan;208(2):176-86 [16362996.001]
  • [Cites] J Gen Virol. 2006 May;87(Pt 5):1047-74 [16603506.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Hum Pathol. 2006 Sep;37(9):1233-6 [16938530.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2597-603 [17148591.001]
  • [Cites] Oncogene. 2007 Aug 2;26(35):5115-23 [17325665.001]
  • [Cites] Adv Anat Pathol. 2007 May;14(3):189-94 [17452815.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3715-21 [17682125.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3813-20 [18230756.001]
  • [Cites] Blood Rev. 2008 Sep;22(5):261-81 [18456377.001]
  • [Cites] Am J Pathol. 2008 Jul;173(1):195-204 [18502823.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1447-52 [9037073.001]
  • [Cites] AIDS. 1997 Oct;11(12):1522-3 [9342077.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):766-74 [9477111.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 4;90(5):364-9 [9498486.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11963-8 [9751773.001]
  • [Cites] Immunity. 1998 Sep;9(3):405-11 [9768760.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1609-14 [9811353.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2119-27 [11684931.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] Dermatology. 2004;208(3):287-90 [15118393.001]
  • [Cites] Clin Infect Dis. 2004 Jun 1;38(11):1629-32 [15156453.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2627-36 [15197806.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4227-8 [15483034.001]
  • [Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]
  • [Cites] Arch Pathol Lab Med. 1999 Mar;123(3):257-60 [10086517.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]
  • [Cites] Crit Rev Oncog. 1998;9(3-4):199-208 [10201628.001]
  • (PMID = 21416008.001).
  • [ISSN] 2035-3006
  • [Journal-full-title] Mediterranean journal of hematology and infectious diseases
  • [ISO-abbreviation] Mediterr J Hematol Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3033170
  •  go-up   go-down


56. Vasilj A, Kojić-Katović S, Maricević I, Zokvić E, Kelcec IB, Tomas D, Curić-Jurić S: Hodgkin's lymphoma variant of Richter's syndrome. Coll Antropol; 2010 Mar;34(1):295-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma variant of Richter's syndrome.
  • Chronic lymphocytic leukemia/small lymphocitic lymphoma (CLL/SLL) is low-grade malignant lymphoprolipheration, that has tendency to convert to a higher-grade neoplasm over time.
  • More common is the development of a diffuse large cell lymphoma or transformation into prolymphocytic cell population.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Reed-Sternberg Cells / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20437646.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


57. Re D, Küppers R, Diehl V: Molecular pathogenesis of Hodgkin's lymphoma. J Clin Oncol; 2005 Sep 10;23(26):6379-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathogenesis of Hodgkin's lymphoma.
  • According to the WHO classification, Hodgkin's lymphoma (HL) is subdivided into a classical variant and a nodular lymphocyte predominant variant which are characterized by the presence of Hodgkin's and Reed-Sternberg (H-RS) cells or lymphocytic and histiocytic (L&H) cells, respectively.
  • We believe that an in-depth understanding of the pathogenesis of HL will eventually lead to the development of novel biologically based therapeutic strategies in the near future.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155023.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Cytokine; 0 / Receptors, Tumor Necrosis Factor
  • [Number-of-references] 78
  •  go-up   go-down


58. Burjanadze M, Matthes T, McKee T, Passweg J, Huard B: In situ detection of APRIL-rich niches for plasma-cell survival and their contribution to B-cell lymphoma development. Histol Histopathol; 2009 08;24(8):1061-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ detection of APRIL-rich niches for plasma-cell survival and their contribution to B-cell lymphoma development.
  • It also provided evidence that APRIL may modulate tumor development in patients, but only for specific B-cell malignancies.
  • [MeSH-major] Lymphoma, B-Cell / immunology. Plasma Cells / metabolism. Tumor Necrosis Factor Ligand Superfamily Member 13 / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19554513.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / B-Cell Activating Factor; 0 / B-Cell Activation Factor Receptor; 0 / Ligands; 0 / Tumor Necrosis Factor Ligand Superfamily Member 13
  • [Number-of-references] 40
  •  go-up   go-down


59. Prabhash K, Biswas G, Nair R, Pandey D, Maru D, Mahajan A, Parikh PM: Metachronous gastric diffuse large B-cell lymphoma and adenocarcinoma. Indian J Gastroenterol; 2006 Sep-Oct;25(5):261-2
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous gastric diffuse large B-cell lymphoma and adenocarcinoma.
  • The development of gastric carcinoma in a patient with gastric lymphoma is rare.
  • We report a 38-year-old lady who was initially diagnosed to have gastric lymphoma and developed early gastric carcinoma on follow up.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphoma, B-Cell / pathology. Neoplasms, Second Primary / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090851.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


60. Breen EC, Fatahi S, Epeldegui M, Boscardin WJ, Detels R, Martínez-Maza O: Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol; 2006;27(4):187-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma.
  • CD30, first described as the Ki antigen on malignant B cells in Hodgkin's lymphoma, is also expressed on normal activated B and T cells.
  • In a cross-sectional study utilizing archived sera at a time point close to but preceding a diagnosis of acquired immunodeficiency syndrome (AIDS)-associated non-Hodgkin's B cell lymphoma, AIDS lymphoma subjects (n = 49) showed elevated mean levels of sCD30 compared to controls with AIDS but no malignancy (n = 44, p < 0.01), HIV-infected but relatively healthy (n = 47, p < 0.001), or HIV-seronegative controls (n = 44, p < 0.001).
  • Serum sCD30 was significantly correlated to serum levels of the B cell cytokines interleukin-6 (IL-6), IL-10, and sCD23, but only among lymphoma subjects (p < or = 0.05).
  • These observations suggest that sCD30, especially in combination with other immune system molecules, could be an important biomarker for an immune system environment conducive to B cell hyperactivation and the development of AIDS-associated B cell lymphoma.
  • [MeSH-major] Antigens, CD30 / blood. Lymphoma, AIDS-Related / immunology. Lymphoma, B-Cell / immunology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16651853.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5-M01-RR-00722; United States / NIAID NIH HHS / AI / AI28697; United States / NCI NIH HHS / CA / CA73475; United States / NCI NIH HHS / CA / CA96888; United States / NIAID NIH HHS / AI / U01-AI-35043; United States / NIAID NIH HHS / AI / UO1-AI-35039; United States / NIAID NIH HHS / AI / UO1-AI-35040; United States / NIAID NIH HHS / AI / UO1-AI-35041; United States / NIAID NIH HHS / AI / UO1-AI-35042; United States / NIAID NIH HHS / AI / UO1-AI-37613; United States / NIAID NIH HHS / AI / UO1-AI-37984
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD30; 0 / Biomarkers; 0 / Interleukins
  •  go-up   go-down


61. Felberbaum RS: The molecular mechanisms of classic Hodgkin's lymphoma. Yale J Biol Med; 2005 Jul;78(4):203-10
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The molecular mechanisms of classic Hodgkin's lymphoma.
  • Classic Hodgkin's lymphoma is characterized by the appearance of giant abnormal cells called Hodgkin and Reed-Sternberg (HRS) cells.
  • This paper reviews several recent studies that for the first time implicate specific molecules in the pathogenesis of classic Hodgkin's lymphoma.
  • Targeting these molecules could lead to the development of novel therapies for this disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720015.001).
  • [ISSN] 1551-4056
  • [Journal-full-title] The Yale journal of biology and medicine
  • [ISO-abbreviation] Yale J Biol Med
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD07149-27
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC2259149
  •  go-up   go-down


62. Verma S, Frambach GE, Seilstad KH, Nuovo G, Porcu P, Magro CM: Epstein--Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin. J Cutan Pathol; 2005 Aug;32(7):474-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein--Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin.
  • BACKGROUND: Epstein-Barr virus (EBV) has been implicated in B-cell lymphoma associated with iatrogenic immune dysregulation, primarily in the context of extracutaneous lymphoma.
  • METHODS: We describe six patients, five transplant recipients receiving cyclosporine and one patient with rheumatoid arthritis receiving methotrexate, who developed cutaneous presentations of EBV-associated B-cell lymphoma.
  • RESULTS: The cases comprised plasmablastic lymphoma (one case), plasmacytic marginal zone lymphoma (two cases), and diffuse large B-cell lymphoma (three cases).
  • CONCLUSIONS: EBV-associated cutaneous B-cell lymphoma is characterized by a long interval between the initiation of immunosuppression and the development of lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / immunology. Herpesvirus 4, Human / isolation & purification. Immunocompromised Host. Lymphoma, B-Cell / immunology. Skin Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008691.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Messenger; 0 / RNA, Viral; EC 2.7.1.21 / Thymidine Kinase
  •  go-up   go-down


63. Hellmig S, Bartscht T, Fischbach W, Ott SJ, Rosenstiel P, Klapper W, Fölsch UR, Schreiber S: Germline variations of the MALT1 gene as risk factors in the development of primary gastric B-cell lymphoma. Eur J Cancer; 2009 Jul;45(10):1865-70
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline variations of the MALT1 gene as risk factors in the development of primary gastric B-cell lymphoma.
  • Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is a histologically distinct tumour derived from MALT acquired as a result of Helicobacter pylori infection.
  • The genetic susceptibility to develop primary gastric B-cell lymphoma in patients with chronic H. pylori infection is unknown.
  • MALT1 plays a key role in malignant B-cell transformation and lymphoma progression.
  • Thus, we investigated germline variations of MALT1 as risk factors for gastric lymphoma in a large cohort from a European multicentre study and in total 214 lymphoma patients, 593 H. pylori infected controls and 348 healthy blood donors were genotyped for four single nucleotide polymorphisms (SNPs) covering the MALT1 locus by Taqman technology.
  • In single marker analysis individuals homozygous for the rare allele G of SNP3 (rs12969413) were significantly protected only from gastric high-grade lymphoma compared with controls (p=0.002, odds ratio (OR): 0.2, Wald 95% confidence interval (CI): 0.1<OR<0.6).
  • This association could not be confirmed in a second independent cohort of high-grade lymphoma patients from the Lymph node registry in Kiel (p=0.531, OR: 0.8, Wald 95% CI: 0.4<OR<1.5).
  • Due to the fact that SNPs 2, 3 and 4 are arranged in one LD block exhibiting nearly complete linkage disequilibrium it is rather unlikely that germline variations of MALT1 might be involved in the pathogenesis of gastric lymphoma.
  • This is the first genetic association study that investigated polymorphisms of MALT1 as genetic risk factors in the development of primary gastric lymphoma.
  • [MeSH-major] Caspases / genetics. Germ-Line Mutation. Lymphoma, B-Cell, Marginal Zone / genetics. Neoplasm Proteins / genetics. Stomach Neoplasms / genetics

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394813.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 3.4.22.- / Caspases; EC 3.4.22.- / MALT1 protein, human
  •  go-up   go-down


64. Middendorp S, Xiao Y, Song JY, Peperzak V, Krijger PH, Jacobs H, Borst J: Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma. Blood; 2009 Sep 10;114(11):2280-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma.
  • We report that mice deficient for CD137 ligand (CD137L) are predisposed to develop B-cell lymphoma, with an incidence of approximately 60% at 12 months of age.
  • Lymphoma membrane markers were characteristic of GC B cells.
  • Longitudinal histologic analysis identified the GC as site of oncogenic transformation and classified 85% of the malignancies found in approximately 200 mice as GC-derived B-cell lymphoma.
  • Among these are proto-oncogenes that mediate GC B-cell lymphoma development in humans.
  • [MeSH-major] 4-1BB Ligand. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic / metabolism. Germinal Center / metabolism. Lymphoma, B-Cell / metabolism. Tumor Suppressor Proteins

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19608748.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-1BB Ligand; 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, CD137; 0 / Bach2 protein, mouse; 0 / Basic-Leucine Zipper Transcription Factors; 0 / Bcl10 protein, mouse; 0 / Bcl6 protein, mouse; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ephrin-A2; 0 / Tnfsf9 protein, mouse; 0 / Tumor Suppressor Proteins; EC 3.5.4.- / AICDA (activation-induced cytidine deaminase); EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


65. Gucalp A, Noy A: Spectrum of HIV lymphoma 2009. Curr Opin Hematol; 2010 Jul;17(4):362-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of HIV lymphoma 2009.
  • This review summarizes the recent progress made in HIV lymphoma research published in 2009 through January 2010.
  • RECENT FINDINGS: The majority of investigation in this field has been in diffuse large B-cell lymphoma, with infusional therapy remaining promising.
  • Risk factors associated with the development of lymphoma include low CD4 cell count and likely cumulative HIV viremia.
  • SUMMARY: Overall, the outcome for HIV lymphoma continues to improve as insights into the pathophysiology and treatment advance.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / methods. HIV Infections / therapy. Lymphoma, AIDS-Related / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. CD4 Lymphocyte Count. Combined Modality Therapy. HIV / drug effects. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / therapy. Rituximab

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20442655.001).
  • [ISSN] 1531-7048
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 36
  •  go-up   go-down


66. Bende RJ, Smit LA, van Noesel CJ: Molecular pathways in follicular lymphoma. Leukemia; 2007 Jan;21(1):18-29
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathways in follicular lymphoma.
  • Follicular lymphoma (FL) is one of the most common B-cell non-Hodgkin's lymphomas.
  • The exact secondary alterations leading to full FL development are still poorly defined.
  • In this review, we address (i) the genetic pathways associated with tumorigenesis and progression of FL, (ii) the role of micro-environmental factors with emphasis on B-cell receptor ligands and (iii) lymphoma models in mice and what they teach us about lymphomagenesis in man.
  • [MeSH-major] Lymphoma, Follicular

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17039231.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Antigen, B-Cell
  • [Number-of-references] 154
  •  go-up   go-down


67. Voulgarelis M, Skopouli FN: Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients. Clin Rev Allergy Immunol; 2007 Jun;32(3):265-74
MedlinePlus Health Information. consumer health - Sjogren's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients.
  • Among autoimmune diseases, Sjogren's syndrome (SS) displays the highest incidence of non-Hodgkin lymphoma (NHL) development with the salivary extranodal marginal zone B cell lymphomas being the most common type.
  • Although the transition from a chronic inflammatory condition to malignant lymphoma is a multistep process yet poorly understood, there is increasing evidence that chronic antigenic stimulation by an exoantigen or autoantigens plays an essential role in the development of SS associated lymphoproliferation.
  • Among the clinical and serological parameters that have been associated with lymphoma development in SS patients, the presence of palpable purpura, low C4, and mixed monoclonal cryoglobulinemia constitute the main predictive markers, and patients displaying these risk factors should be monitored closely.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / immunology. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / immunology. Sjogren's Syndrome / complications

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Rheumatol. 1999 May-Jun;17(3):339-42 [10410268.001]
  • [Cites] Am J Clin Pathol. 1991 Dec;96(6):738-45 [1746490.001]
  • [Cites] J Immunol. 2004 Jan 15;172(2):812-22 [14707051.001]
  • [Cites] Arthritis Rheum. 1989 Jul;32(7):859-69 [2546568.001]
  • [Cites] Ann Rheum Dis. 1990 Nov;49(11):929-31 [2124096.001]
  • [Cites] Leuk Lymphoma. 1999 Mar;33(1-2):93-9 [10194125.001]
  • [Cites] Clin Exp Immunol. 1972 Feb;10(2):199-221 [4625796.001]
  • [Cites] Am J Pathol. 1997 Nov;151(5):1361-9 [9358762.001]
  • [Cites] J Clin Invest. 2002 Jan;109(1):59-68 [11781351.001]
  • [Cites] Blood. 1997 Jul 15;90(2):766-75 [9226177.001]
  • [Cites] Arthritis Rheum. 2000 Apr;43(4):908-16 [10765938.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S126-32 [9894477.001]
  • [Cites] N Engl J Med. 1978 Nov 30;299(22):1215-20 [309554.001]
  • [Cites] J Rheumatol. 1997 Dec;24(12):2376-80 [9415645.001]
  • [Cites] Clin Exp Immunol. 1990 Dec;82(3):509-14 [2124958.001]
  • [Cites] Curr Opin Oncol. 1996 May;8(3):232-7 [8804813.001]
  • [Cites] Blood. 1997 May 1;89(9):3335-44 [9129040.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2489-95 [12456507.001]
  • [Cites] Semin Arthritis Rheum. 1998 Oct;28(2):80-7 [9806368.001]
  • [Cites] Hematology. 2002 Aug;7(4):239-52 [14972786.001]
  • [Cites] Immunol Today. 1996 Aug;17(8):354-6 [8783493.001]
  • [Cites] Arthritis Rheum. 1999 Aug;42(8):1765-72 [10446879.001]
  • [Cites] Clin Exp Rheumatol. 1988 Jul-Sep;6(3):247-52 [3141095.001]
  • [Cites] Ann Oncol. 2000 May;11(5):521-6 [10907943.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982;395(1):11-43 [7043890.001]
  • [Cites] Br J Rheumatol. 1995 Apr;34(4):326-33 [7788146.001]
  • [Cites] J Immunol. 1983 Jun;130(6):2663-5 [6406594.001]
  • [Cites] Scand J Immunol. 2001 Oct;54(4):421-7 [11555410.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3018-24 [9787134.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2160-71 [12209521.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):937-9 [11521798.001]
  • [Cites] Semin Arthritis Rheum. 1996 Apr;25(5):337-46 [8778989.001]
  • [Cites] Ann Rheum Dis. 2003 Feb;62(2):168-71 [12525388.001]
  • [Cites] Rheumatology (Oxford). 2005 Jan;44(1):89-94 [15381790.001]
  • [Cites] Arthritis Rheum. 1997 Feb;40(2):318-31 [9041944.001]
  • [Cites] Arthritis Rheum. 1999 Jul;42(7):1466-72 [10403275.001]
  • [Cites] Hum Pathol. 1993 Oct;24(10):1040-57 [8406414.001]
  • [Cites] J Immunol. 1986 Jan;136(2):477-83 [3079786.001]
  • [Cites] Arthritis Rheum. 1997 Jan;40(1):87-97 [9008604.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):4-12 [10658904.001]
  • [Cites] Arch Intern Med. 2005 Nov 14;165(20):2337-44 [16287762.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3878-84 [10845923.001]
  • [Cites] Eur J Immunol. 1997 Jul;27(7):1751-5 [9247587.001]
  • [Cites] J Clin Invest. 1998 Sep 1;102(5):938-46 [9727062.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):476-80 [14760068.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1697-710 [10587360.001]
  • [Cites] Semin Arthritis Rheum. 2000 Apr;29(5):296-304 [10805354.001]
  • [Cites] Ann Rheum Dis. 1985 Feb;44(2):109-12 [3919659.001]
  • [Cites] Arthritis Rheum. 1986 Sep;29(9):1098-104 [3489468.001]
  • [Cites] Am J Med. 1964 Apr;36:529-40 [14142406.001]
  • [Cites] Lab Invest. 2003 Mar;83(3):357-65 [12649336.001]
  • [Cites] Arthritis Rheum. 1996 May;39(5):767-72 [8639173.001]
  • [Cites] Ann Rheum Dis. 1986 Mar;45(3):210-9 [3082300.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S94-103 [9894474.001]
  • [Cites] Blood. 1998 Mar 15;91(6):1864-72 [9490668.001]
  • [Cites] Am J Pathol. 1993 Jan;142(1):285-92 [8424461.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] J Immunol. 1986 Jul 1;137(1):122-8 [3086444.001]
  • [Cites] Ann Intern Med. 1978 Dec;89(6):888-92 [102228.001]
  • [Cites] Am J Pathol. 1996 Feb;148(2):643-8 [8579126.001]
  • [Cites] Lab Invest. 1999 Mar;79(3):261-9 [10092062.001]
  • [Cites] Arthritis Rheum. 2003 May;48(5):1332-42 [12746906.001]
  • [Cites] Lancet Oncol. 2002 Feb;3(2):97-104 [11902529.001]
  • [Cites] Ann Rheum Dis. 2006 Jun;65(6):796-803 [16284097.001]
  • [Cites] Arthritis Rheum. 2001 Jun;44(6):1313-9 [11407690.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1254 [10561186.001]
  • [Cites] J Immunol. 1983 Jan;130(1):203-8 [6600176.001]
  • [Cites] Medicine (Baltimore). 2005 Mar;84(2):90-7 [15758838.001]
  • [Cites] Arthritis Rheum. 2002 Dec;46(12):3151-8 [12483718.001]
  • [Cites] Arthritis Rheum. 2002 Mar;46(3):741-7 [11920410.001]
  • [Cites] J Exp Med. 1991 Nov 1;174(5):1245-50 [1940802.001]
  • [Cites] J Rheumatol. 1995 Sep;22(9):1674-80 [8523344.001]
  • [Cites] Blood. 2000 Feb 1;95(3):802-6 [10648389.001]
  • [Cites] Blood. 1995 Dec 15;86(12):4587-93 [8541549.001]
  • (PMID = 17992593.001).
  • [ISSN] 1080-0549
  • [Journal-full-title] Clinical reviews in allergy & immunology
  • [ISO-abbreviation] Clin Rev Allergy Immunol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 74
  •  go-up   go-down


68. Svajdler M, Lazúrová I, Bohus P, Pal'ko M: Intravascular variant of diffuse large B-cell lymphoma with combined endocrine involvement. Wien Klin Wochenschr; 2006 Jul;118(13-14):422-5
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular variant of diffuse large B-cell lymphoma with combined endocrine involvement.
  • The intravascular variant of diffuse large B-cell lymphoma (IVBL) is a rare form of non-Hodgkin lymphoma that is frequently diagnosed at autopsy because the symptoms are nonspecific or confusing.
  • We report a case of IVBL in a woman with pre-existing myelodysplastic syndrome manifested as a fever of unknown origin, bilateral adrenal enlargement and subsequent development of panhypopituitarism.
  • An intravascular variant of B-cell lymphoma with intravascular collections of lymphomatous cells predominantly localized in the adrenal and pituitary glands was found at autopsy.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Multiple Endocrine Neoplasia / diagnosis. Pituitary Neoplasms / diagnosis. Vascular Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cesk Patol. 2003 Jan;39(1):21-5 [12673939.001]
  • [Cites] Am J Surg Pathol. 1986 Feb;10(2):112-23 [2420221.001]
  • [Cites] Am J Hematol. 2003 Nov;74(3):211-3 [14587055.001]
  • [Cites] Arch Pathol Lab Med. 2003 Oct;127(10):1380-2 [14521449.001]
  • [Cites] Mod Pathol. 1996 May;9(5):534-43 [8733769.001]
  • [Cites] Cancer. 1990 Oct 15;66(8):1781-8 [1698530.001]
  • [Cites] Histopathology. 1997 Aug;31(2):161-6 [9279568.001]
  • [Cites] Cancer. 1993 May 15;71(10):3156-64 [8490846.001]
  • [Cites] Arch Pathol Lab Med. 2001 Jul;125(7):948-50 [11419984.001]
  • [Cites] Arch Pathol Lab Med. 1999 Apr;123(4):335-7 [10320147.001]
  • [Cites] Ann Dermatol Venereol. 2002 Mar;129(3):320-4 [11988690.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1738-45 [8156502.001]
  • [Cites] Hautarzt. 1959 Aug;10:359-63 [14432547.001]
  • (PMID = 16865648.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


69. Kelly PN, Puthalakath H, Adams JM, Strasser A: Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma. Blood; 2007 Jun 1;109(11):4907-13
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma.
  • Although myc and bcl-2 synergize in tumor development, particularly lymphomagenesis, it is not known whether endogenous bcl-2 is required for myc-induced tumorigenesis.
  • However, despite the striking reduction in B-cell numbers in vivo, ablation of endogenous Bcl-2 did not prevent or even delay development of Emu-myc lymphoma.
  • These findings demonstrate that the initiation, development, continued growth, and severity of Emu-myc lymphoma do not depend upon endogenous Bcl-2, nor upon the total number of B lymphoid cells driven by the Emu-myc transgene.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2658-69 [10541552.001]
  • [Cites] Mol Cell Biol. 2001 Aug;21(15):5063-70 [11438662.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(22):7653-62 [11604501.001]
  • [Cites] Dev Cell. 2001 Nov;1(5):645-53 [11709185.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):289-98 [12086865.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):647-56 [12209154.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] J Cell Biol. 2004 Jan 5;164(1):89-96 [14709542.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6164-9 [15079075.001]
  • [Cites] J Immunol. 2004 Jun 1;172(11):6684-91 [15153484.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9333-8 [15192153.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):241-9 [15380515.001]
  • [Cites] Science. 1984 Jun 29;224(4656):1403-6 [6610211.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Nov;81(22):7166-70 [6334305.001]
  • [Cites] Nature. 1985 Dec 12-18;318(6046):533-8 [3906410.001]
  • [Cites] Cell. 1986 Oct 10;47(1):11-8 [3093082.001]
  • [Cites] J Exp Med. 1988 Feb 1;167(2):353-71 [3258007.001]
  • [Cites] N Engl J Med. 1988 Jun 23;318(25):1638-44 [3287162.001]
  • [Cites] Nature. 1988 Sep 29;335(6189):440-2 [3262202.001]
  • [Cites] N Engl J Med. 1989 Apr 20;320(16):1047-54 [2648153.001]
  • [Cites] Cell. 1989 Apr 7;57(1):79-88 [2649247.001]
  • [Cites] Nature. 1990 Nov 22;348(6299):331-3 [2250704.001]
  • [Cites] Curr Top Microbiol Immunol. 1990;166:175-81 [2073796.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8661-5 [1924327.001]
  • [Cites] Cell. 1992 Apr 3;69(1):119-28 [1555236.001]
  • [Cites] Oncogene. 1993 Jan;8(1):1-9 [8423986.001]
  • [Cites] J Exp Med. 1993 Sep 1;178(3):951-60 [8350062.001]
  • [Cites] Science. 1993 Sep 17;261(5128):1584-8 [8372353.001]
  • [Cites] Cell. 1993 Oct 22;75(2):229-40 [8402909.001]
  • [Cites] EMBO J. 1994 Feb 1;13(3):683-91 [8313913.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3700-4 [8170972.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):354-9 [7812968.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1506-10 [7878471.001]
  • [Cites] Immunity. 1994 Sep;1(6):517-27 [7895160.001]
  • [Cites] J Exp Med. 1996 Feb 1;183(2):381-91 [8627151.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2219-26 [8642331.001]
  • [Cites] EMBO J. 1996 Aug 1;15(15):3823-34 [8670887.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9545-52 [8790367.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):6979-90 [9003774.001]
  • [Cites] Oncogene. 1999 May 13;18(19):2967-87 [10378693.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):876-85 [16239906.001]
  • [Cites] Annu Rev Biochem. 2000;69:217-45 [10966458.001]
  • (PMID = 17317859.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA043540; United States / NCI NIH HHS / CA / R01 CA080188; United States / NCI NIH HHS / CA / CA 43540; United States / NCI NIH HHS / CA / CA 80188
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ PMC1885522
  •  go-up   go-down


70. Fabris M, Quartuccio L, Salvin S, Pozzato G, De Re V, Mazzaro C, Ferri C, Baldini C, De Vita S: Fibronectin gene polymorphisms are associated with the development of B-cell lymphoma in type II mixed cryoglobulinemia. Ann Rheum Dis; 2008 Jan;67(1):80-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibronectin gene polymorphisms are associated with the development of B-cell lymphoma in type II mixed cryoglobulinemia.
  • OBJECTIVE: To analyse fibronectin (FN) gene polymorphisms in type II mixed cryoglobulinemic syndrome (MCsn), an immune-complex mediated systemic vasculitis linked to hepatitis C virus (HCV) infection and characterised by rheumatoid factor (RF) positive B-cell proliferation at high risk for the progression into non-Hodgkin's lymphoma (NHL).
  • Of note, the DD-MspI (OR = 5.99; CI 1.77-20.261, p = 0.0039) and the AA-HaeIIIb (OR = 4.82, CI 1.42-16.39, p = 0.0176) homozygosis appeared significantly associated with the development of B-cell NHL in MCsn patients, with the HaeIIIb A allele possibly conferring an increased risk of NHL in the general population (OR = 1.72, CI 1.128-2.635, p = 0.0133).
  • CONCLUSION: Genotyping for MspI and HaeIIIb FN gene polymorphisms may be clinically relevant to define the risk of lymphoma development in MCsn.
  • [MeSH-major] Cryoglobulinemia / genetics. Fibronectins / genetics. Lymphoma, B-Cell / genetics. Polymorphism, Genetic
  • [MeSH-minor] Case-Control Studies. Gene Frequency. Genotype. Hepacivirus. Hepatitis C / complications. Humans. Lymphoma, Non-Hodgkin / complications. Risk Assessment / methods. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Cryoglobulinemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17526550.001).
  • [ISSN] 1468-2060
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fibronectins
  •  go-up   go-down


71. Ziemer M, Bauer HI, Fluhr JW, Kaatz M, Elsner P: Primary cutaneous follicle center lymphoma -'crosti lymphoma': what can we learn? Am J Clin Dermatol; 2008;9(2):133-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous follicle center lymphoma -'crosti lymphoma': what can we learn?
  • Reticulo-histiocytoma of the back was later classified as a primary cutaneous follicle center lymphoma (PCFCL).
  • ' Persistent antigenic stimulation of lymphocytes in a neoplastic process or by an antigen, for example, Borrelia burgdorferi, can lead to transformation and cell division with development of large blast cells.
  • Although the association of primary cutaneous B-cell lymphoma with Borrelia infection is known, there are still difficulties in differentiating the condition from pseudolymphoma.
  • It is also important to recognize that inability to verify monoclonality should not exclude the diagnosis of lymphoma.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Follicular / diagnosis. Pseudolymphoma / diagnosis. Skin / pathology. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18284269.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antibodies, Bacterial
  •  go-up   go-down


72. Howe D, Bromidge T: Variation of LEF-1 mRNA expression in low-grade B-cell non-Hodgkin's lymphoma. Leuk Res; 2006 Jan;30(1):29-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation of LEF-1 mRNA expression in low-grade B-cell non-Hodgkin's lymphoma.
  • During normal B-lymphocyte development once cells pass the pro-B stage the transcription factor LEF-1, a key component of the Wnt/beta-catenin pathway, is down regulated.
  • This study demonstrates that although LEF-1 mRNA is universally, highly expressed in B-CLL, expression of this gene is much lower or absent in the majority of low-grade B-cell non-Hodgkin's lymphoma (NHL).
  • [MeSH-major] Down-Regulation. Gene Expression Regulation, Leukemic. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lymphoid Enhancer-Binding Factor 1 / biosynthesis. Lymphoma, Non-Hodgkin / metabolism. Neoplasm Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16054689.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Lymphoid Enhancer-Binding Factor 1; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


73. God JM, Haque A: Burkitt lymphoma: pathogenesis and immune evasion. J Oncol; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma: pathogenesis and immune evasion.
  • B-cell lymphomas arise at distinct stages of cellular development and maturation, potentially influencing antigen (Ag) presentation and T-cell recognition.
  • Burkitt lymphoma (BL) is a highly malignant B-cell tumor associated with Epstein-Barr Virus (EBV) infection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20953370.001).
  • [ISSN] 1687-8469
  • [Journal-full-title] Journal of oncology
  • [ISO-abbreviation] J Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA129560
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2952908
  •  go-up   go-down


74. Gladden AB, Woolery R, Aggarwal P, Wasik MA, Diehl JA: Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene; 2006 Feb 16;25(7):998-1007
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma.
  • Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by overexpression of cyclin D1 due to the t(11;14) chromosomal translocation.
  • While expression of cyclin D1 correlates with MCL development, expression of wild-type (WT) cyclin D1 transgene in murine lymphocytes is unable to drive B-cell lymphoma.
  • D1/T286A transgenic mice universally develop a mature B-cell lymphoma.
  • Lymphoma onset correlates with perturbations in p53/MDM2/p19Arf expression and with BcL-2 overexpression suggesting that alterations in one or both of these pathways may contribute to lymphoma development.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Cancer Res. 1996;68:67-108 [8712071.001]
  • [Cites] Jpn J Cancer Res. 1996 May;87(5):459-65 [8641982.001]
  • [Cites] Oncogene. 1996 Dec 5;13(11):2431-7 [8957085.001]
  • [Cites] Cell. 1997 Feb 7;88(3):323-31 [9039259.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2067-78 [9058729.001]
  • [Cites] Genes Dev. 1997 Apr 1;11(7):847-62 [9106657.001]
  • [Cites] Genes Dev. 1997 Apr 15;11(8):957-72 [9136925.001]
  • [Cites] Mol Cell Biol. 1997 Dec;17(12):7362-74 [9372967.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):567-75 [9452276.001]
  • [Cites] Genes Dev. 1998 Aug 1;12(15):2424-33 [9694806.001]
  • [Cites] Genes Dev. 1998 Nov 15;12(22):3499-511 [9832503.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):616-9 [10225453.001]
  • [Cites] Mol Cancer Ther. 2004 Nov;3(11):1427-38 [15542782.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2658-69 [10541552.001]
  • [Cites] Leukemia. 1999 Dec;13(12):2087-93 [10602433.001]
  • [Cites] Genes Dev. 2000 Dec 15;14(24):3102-14 [11124803.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3902-9 [11389033.001]
  • [Cites] Haematologica. 2001 Jun;86(6):563-9 [11418364.001]
  • [Cites] Mol Cell Biol. 2001 Aug;21(15):5063-70 [11438662.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(22):7653-62 [11604501.001]
  • [Cites] Leuk Res. 2002 Sep;26(9):849-55 [12127561.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1430-7 [12149228.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):434-41 [12580957.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):185-97 [12620412.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9754-60 [12519773.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):30339-47 [12746453.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7056-61 [14612495.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8226-32 [14678979.001]
  • [Cites] EMBO J. 1984 Jun;3(6):1209-19 [6086308.001]
  • [Cites] Nature. 1985 Dec 12-18;318(6046):533-8 [3906410.001]
  • [Cites] Mol Cell Biol. 1989 Sep;9(9):3973-81 [2550808.001]
  • [Cites] Immunol Today. 1990 Oct;11(10):361-8 [2145852.001]
  • [Cites] Oncogene. 1992 Jul;7(7):1401-6 [1535701.001]
  • [Cites] Nature. 1992 Oct 8;359(6395):552-4 [1406975.001]
  • [Cites] Nature. 1992 Oct 8;359(6395):554-6 [1406976.001]
  • [Cites] Oncogene. 1993 Jan;8(1):1-9 [8423986.001]
  • [Cites] Genes Dev. 1993 Aug;7(8):1559-71 [8339933.001]
  • [Cites] Cancer Res. 1994 Jan 15;54(2):377-9 [8275473.001]
  • [Cites] Oncogene. 1994 Jan;9(1):323-6 [8302597.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):2066-76 [8114738.001]
  • [Cites] EMBO J. 1994 May 1;13(9):2124-30 [8187765.001]
  • [Cites] EMBO J. 1994 Aug 1;13(15):3487-95 [8062825.001]
  • [Cites] Genes Dev. 1994 Aug 1;8(15):1750-8 [7958854.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1672-7 [8939849.001]
  • (PMID = 16247460.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093237; United States / NCI NIH HHS / CA / CA093237-05; United States / NCI NIH HHS / CA / CA93237; United States / NCI NIH HHS / CA / R01 CA093237-05; United States / NCI NIH HHS / CA / R01 CA089194; United States / NCI NIH HHS / CA / CA89194
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin M; 136601-57-5 / Cyclin D1; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  • [Other-IDs] NLM/ NIHMS178033; NLM/ PMC2832762
  •  go-up   go-down


75. Hsi ED: Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment. Leuk Lymphoma; 2008 Sep;49(9):1668-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment.
  • Classical Hodgkin lymphoma is now recognised as a B-cell lymphoma.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18798102.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 138
  •  go-up   go-down


76. Janz M, Dörken B, Mathas S: Reprogramming of B lymphoid cells in human lymphoma pathogenesis. Cell Cycle; 2006 May;5(10):1057-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reprogramming of B lymphoid cells in human lymphoma pathogenesis.
  • Using lymphoid development as a model system, recent data have challenged this rigid view of cellular differentiation.
  • Recent data from our laboratory have demonstrated that similar processes can be observed in the malignant Hodgkin/Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL), a common B cell-derived lymphoma.
  • We first summarize data showing the plasticity of lymphoid cells in mouse models, second describe our observations regarding the altered B cell-specific transcription factor network in HRS cells, and third discuss the possible implications of these findings for human lymphoma pathogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16687930.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Inhibitor of Differentiation Protein 2; 0 / MSC protein, human; 0 / TCF3 protein, human
  •  go-up   go-down


77. Sheen-Chen SM, Eng HL: Development of malignant lymphoma subsequent to breast cancer. Eur J Cancer Care (Engl); 2007 Jul;16(4):331-2
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of malignant lymphoma subsequent to breast cancer.
  • The development of malignant lymphoma following breast cancer has not been described before.
  • Here we report the development of malignant lymphoma at the ipsilateral chest wall subsequent to the surgical treatment of breast cancer.
  • Excisional biopsy was performed and eventually was histologically diagnosed to be malignant lymphoma.
  • In view of the therapeutic implication, the development of second malignancy should not be mistaken as a progression of the known primary malignancy.
  • [MeSH-major] Breast Neoplasms / surgery. Lymphoma / etiology. Mastectomy, Modified Radical. Neoplasms, Second Primary / etiology. Postoperative Complications / etiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587356.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


78. Buske C, Unterhalt M, Hiddeman W: [Therapy of follicular lymphoma]. Internist (Berl); 2007 Apr;48(4):372-81
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy of follicular lymphoma].
  • The treatment options for patients with follicular lymphoma have substantially improved in the last years, in particular with the development of innovative, antibody-based therapeutic strategies.
  • Thus, the anti-CD20 antibody rituximab is one of the cornerstones in the therapy of follicular lymphoma today.
  • Current trials are underway testing whether, for example, the sequential application of a rituximab/chemotherapy induction, myeloablative consolidation therapy followed by autologous stem cell transplantation and rituximab maintenance further improves the therapeutic outcome in follicular lymphoma, or even has curative potential in a subgroup of patients with this disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Follicular / therapy. Radioimmunotherapy / methods. Radioimmunotherapy / trends

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] Blood. 2005 May 15;105(10):3817-23 [15687232.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4416-23 [14976046.001]
  • [Cites] Blood. 2003 Jul 1;102(1):408; author reply 408-9 [12814917.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1504-8 [16690968.001]
  • [Cites] Ann Hematol. 2007 Feb;86(2):81-7 [17068667.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4003-8 [16946304.001]
  • [Cites] Leuk Res. 2006 Mar;30 Suppl 1:S11-5 [16750673.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Br J Cancer. 1994 Jun;69(6):1088-93 [8198975.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2667-74 [15238420.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3295-301 [16873669.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2540-4 [16835383.001]
  • (PMID = 17287964.001).
  • [ISSN] 0020-9554
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents
  • [Number-of-references] 19
  •  go-up   go-down


79. Ferreri AJ, Ernberg I, Copie-Bergman C: Infectious agents and lymphoma development: molecular and clinical aspects. J Intern Med; 2009 Apr;265(4):421-38
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infectious agents and lymphoma development: molecular and clinical aspects.
  • This review is focused on the role of infectious agents in the development of some lymphoma entities.
  • Some paradigmatic examples of these associations include the Helicobacter pylori-related gastric MALT lymphoma and the more recently reported links between Chlamydophila psittaci and ocular adnexal MALT lymphomas and Borrelia burgdorferi and cutaneous MALT lymphomas.
  • [MeSH-major] Borrelia Infections / complications. Chlamydophila Infections / complications. Epstein-Barr Virus Infections / complications. Helicobacter Infections / complications. Helicobacter pylori. Lymphoma, B-Cell / microbiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19298458.001).
  • [ISSN] 1365-2796
  • [Journal-full-title] Journal of internal medicine
  • [ISO-abbreviation] J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 125
  •  go-up   go-down


80. Emmanouilides C: [Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status]. Rev Esp Med Nucl; 2006 Jan-Feb;25(1):42-54
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status].
  • Radioimmunotherapy treatment for lymphoma is a novel targeted therapeutic approach.
  • Several years of development of radioimmunotherapeutic compounds came to fruition in February of 2002 when 90Y-ibritumomab tiuxetan (Zevalin, Y2B8) was approved in the USA and later in Europe, for the treatment of relapsed or refractory, low grade or transformed B-cell lymphoma in the USA.
  • This product has become available in Europe, with simplified administration, for the treatment of relapsed follicular lymphoma.
  • Radioimmunotherapy has been shown to be an effective and clinically relevant complementary therapeutic approach for patients with lymphoma, bringing the Nuclear Medicine into lymphoma therapeutics.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Immunoconjugates / therapeutic use. Iodine Radioisotopes / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy. Yttrium Radioisotopes / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antibody Specificity. Antigens, CD / immunology. Antigens, CD20 / immunology. Antigens, Neoplasm / immunology. Clinical Trials as Topic. Drug Resistance, Neoplasm. European Union. Forecasting. Humans. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / radiotherapy. Patient Selection. Rituximab. Salvage Therapy. Tetraspanins. Treatment Outcome. United States

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rev Esp Med Nucl. 2006 Mar-Apr;25(2):77-9 [16759612.001]
  • (PMID = 16540013.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / Antigens, CD20; 0 / Antigens, Neoplasm; 0 / CD37 protein, human; 0 / Immunoconjugates; 0 / Iodine Radioisotopes; 0 / Tetraspanins; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 0 / iodine-131 anti-B1 antibody; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 66
  •  go-up   go-down


81. Coupland SE, Chan CC, Smith J: Pathophysiology of retinal lymphoma. Ocul Immunol Inflamm; 2009 Jul-Aug;17(4):227-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathophysiology of retinal lymphoma.
  • Retinal lymphoma, the most common form of intraocular lymphoma, is a high-grade malignancy, usually of B-cell type, and is associated with a poor prognosis because of frequent central nervous system (CNS) involvement.
  • The neoplastic B-cells of retinal lymphoma have a characteristic morphology and immunophenotype, express certain chemokines and chemokine receptors, and produce interleukins (IL), e.g. IL-10.
  • Further investigations, such as gene expression profiling, are required to identify oncogenic pathways potentially involved in retinal lymphoma development, and to identify new prognostic/therapeutic markers for this tumor.
  • [MeSH-major] Lymphoma / pathology. Lymphoma / physiopathology. Retinal Neoplasms / pathology. Retinal Neoplasms / physiopathology
  • [MeSH-minor] Chemokines / metabolism. Fundus Oculi. Genotype. Humans. Immunophenotyping. Interleukin-10 / metabolism. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / physiopathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / physiopathology. Prognosis. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 2007 Sep;114(3):271-6 [17641901.001]
  • [Cites] Br J Haematol. 2007 Sep;138(6):749-55 [17760806.001]
  • [Cites] Br J Ophthalmol. 2008 Feb;92(2):297-9 [18227216.001]
  • [Cites] Leukemia. 2008 Feb;22(2):400-5 [17989719.001]
  • [Cites] Am J Ophthalmol. 2009 May;147(5):764-5 [19376328.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Trans Am Ophthalmol Soc. 2003;101:275-92 [14971583.001]
  • [Cites] Br J Haematol. 2004 Feb;124(4):469-73 [14984496.001]
  • [Cites] Ophthalmologe. 2004 Jan;101(1):87-98 [14986704.001]
  • [Cites] Ocul Immunol Inflamm. 2004 Mar;12(1):7-16 [15209459.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):159-66 [15215171.001]
  • [Cites] Clin Lymphoma. 2004 Jun;5(1):19-28 [15245604.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3498-506 [15337798.001]
  • [Cites] N Engl J Med. 1987 Nov 5;317(19):1185-9 [3657890.001]
  • [Cites] Ocul Immunol Inflamm. 2008 Jan-Feb;16(1):29-33 [18379939.001]
  • [Cites] Int J Lab Hematol. 2008 Jun;30(3):230-9 [18479302.001]
  • [Cites] Surv Ophthalmol. 2008 May-Jun;53(3):285-95 [18501272.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3777-84 [18559596.001]
  • [Cites] Jpn J Ophthalmol. 2008 May-Jun;52(3):167-74 [18661266.001]
  • [Cites] Clin Experiment Ophthalmol. 2008 Aug;36(6):564-78 [18954321.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4738-45 [18552383.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):2107-15 [19276283.001]
  • [Cites] Am J Ophthalmol. 2009 May;147(5):886-94, 894.e1 [19243734.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5242-7 [11431365.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1861-74 [11748286.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2285-90 [11895757.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Pathologe. 2002 Jul;23(4):284-91 [12185781.001]
  • [Cites] Blood. 2003 Feb 1;101(3):815-21 [12393412.001]
  • [Cites] Ophthalmology. 2003 Feb;110(2):421-6 [12578791.001]
  • [Cites] Clin Experiment Ophthalmol. 2003 Apr;31(2):155-8 [12648051.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1777-85 [12724484.001]
  • [Cites] Ophthalmology. 2003 Aug;110(8):1671-2 [12917196.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2003 Oct;241(10):860-70 [14605902.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):835-53 [3286832.001]
  • [Cites] Arch Ophthalmol. 1989 Sep;107(9):1349-53 [2675806.001]
  • [Cites] J Exp Med. 1989 Dec 1;170(6):2081-95 [2531194.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1890-3 [1371884.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1289-98 [1325212.001]
  • [Cites] Eur J Immunol. 1992 Nov;22(11):2937-42 [1330578.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):231-6 [8508412.001]
  • [Cites] Blood. 1993 Oct 1;82(7):2261-2 [8400277.001]
  • [Cites] J Clin Invest. 1994 Jan;93(1):424-8 [8282815.001]
  • [Cites] J Immunol. 1995 Jan 15;154(2):718-29 [7814878.001]
  • [Cites] Am J Ophthalmol. 1995 Nov;120(5):671-3 [7485372.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2918-29 [8639912.001]
  • [Cites] J Immunol. 1997 May 1;158(9):4045-51 [9126962.001]
  • [Cites] Arch Ophthalmol. 1997 Sep;115(9):1157-60 [9298057.001]
  • [Cites] Blood. 1999 Sep 1;94(5):1738-46 [10477699.001]
  • [Cites] Br J Ophthalmol. 2004 Dec;88(12):1498-9 [15548797.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2004 Nov;242(11):901-13 [15565454.001]
  • [Cites] Br J Ophthalmol. 2005 Feb;89(2):238-9 [15665359.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Feb;46(2):415-9 [15671263.001]
  • [Cites] J Neurol Sci. 2005 Feb 15;228(2):143-7 [15694195.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2005 Mar;243(3):189-97 [15806372.001]
  • [Cites] Blood. 2005 Jul 1;106(1):384-5 [15967804.001]
  • [Cites] Arch Pathol Lab Med. 2005 Aug;129(8):1050-3 [16048400.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1392-9 [15870177.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):739-49, viii [16083834.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3507-14 [16186327.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3183-90 [16046532.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Nov;46(11):3957-64 [16249468.001]
  • [Cites] Blood. 2006 Jan 1;107(1):190-6 [16150948.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1152-6 [16489068.001]
  • [Cites] J Exp Med. 2006 Feb 20;203(2):311-7 [16492805.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Jul;47(7):2750-6 [16799010.001]
  • [Cites] Curr Opin Ophthalmol. 2006 Dec;17(6):523-31 [17065920.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10586-93 [17079483.001]
  • [Cites] Neurosurg Focus. 2006;21(5):E1 [17134111.001]
  • [Cites] Ophthalmology. 2004 Sep;111(9):1762-7 [15350334.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2077-86 [10595937.001]
  • [Cites] Science. 1999 Dec 10;286(5447):2098-102 [10617422.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Ophthalmology. 2001 Mar;108(3):426-7 [11237883.001]
  • [Cites] Annu Rev Immunol. 2001;19:683-765 [11244051.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3992-4 [11389046.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):805-12 [17327602.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Mar;66(3):230-7 [17356384.001]
  • [Cites] Am J Clin Pathol. 2007 Apr;127(4):633-41 [17369141.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):5042-54 [17510437.001]
  • [Cites] Int Ophthalmol. 2007 Aug;27(4):241-50 [17440686.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3223-9 [17591892.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3253-9 [17591896.001]
  • (PMID = 19657975.001).
  • [ISSN] 1744-5078
  • [Journal-full-title] Ocular immunology and inflammation
  • [ISO-abbreviation] Ocul. Immunol. Inflamm.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 EY000222-22
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokines; 130068-27-8 / Interleukin-10
  • [Number-of-references] 90
  • [Other-IDs] NLM/ NIHMS138865; NLM/ PMC2769503
  •  go-up   go-down


82. Dou HJ, Hu JP: [Progress of study on survivin in diffuse large B-cell lymphoma--review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec;16(6):1487-90
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Progress of study on survivin in diffuse large B-cell lymphoma--review].
  • Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL), which is also a significantly heterogeneous disease.
  • Survivin, a unique member of the inhibitor of apoptosis (IAP) family, is overexpressed in various cancers, including some types of lymphoma.
  • It is found that inhibitor of apoptosis protein, survivin, plays an important role in the development and progression of DLBCL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099670.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Microtubule-Associated Proteins
  •  go-up   go-down


83. Romesser PB, Perlman DH, Faller DV, Costello CE, McComb ME, Denis GV: Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma. Am J Pathol; 2009 Jul;175(1):25-35
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma.
  • New diagnostics and treatment modalities are urgently needed for these lymphomas, particularly in drug development for cancer-specific targets.
  • Previously, we showed that a subset of B cell lymphoma, diffuse large B cell lymphoma, may be characterized by two major, orthogonal axes of gene expression: one set of transcripts that is differentially expressed between resting and proliferating, nonmalignant cells (ie, a "proliferative signature") and another set that is expressed only in proliferating malignant cells (ie, a "cancer signature").
  • Here, we use a murine model of diffuse large B cell lymphoma to conduct unbiased two-dimensional gel electrophoresis and mass spectrometry-based comparative proteomic analyses of malignant proliferating B cells and tissue-matched, normal resting, or normal proliferating cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2000 Oct;20(19):7146-59 [10982831.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Annu Rev Med. 2002;53:303-18 [11818476.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(8):2598-606 [11909954.001]
  • [Cites] Cancer Lett. 2002 Sep 26;183(2):215-20 [12065097.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2572-7 [12239171.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6418-23 [12438227.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):49047-54 [12374812.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8862-70 [12483538.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):543-54 [12509453.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):100-6 [12517784.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):198-207 [12634793.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):208-15 [12634794.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):226-32 [12634796.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1240-7 [12684390.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1475-84 [14563639.001]
  • [Cites] Proteomics. 2004 Feb;4(2):442-7 [14760715.001]
  • [Cites] Proteomics. 2004 Mar;4(3):766-83 [14997498.001]
  • [Cites] J Struct Biol. 2004 Apr-May;146(1-2):44-57 [15037236.001]
  • [Cites] Mol Biol Cell. 2004 Apr;15(4):1862-70 [14767071.001]
  • [Cites] J Cell Biol. 2004 May 10;165(3):421-32 [15138294.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3371-5 [15150086.001]
  • [Cites] Mol Cell Biol. 2004 Jul;24(13):6000-10 [15199153.001]
  • [Cites] Oncogene. 1999 Jun 10;18(23):3501-10 [10376528.001]
  • [Cites] Curr Opin Cell Biol. 1999 Jun;11(3):363-71 [10395553.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8585-94 [15574765.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):291-2 [15659732.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):523-33 [15684406.001]
  • [Cites] Mol Cells. 2005 Apr 30;19(2):289-93 [15879716.001]
  • [Cites] Biochemistry. 2005 Jul 12;44(27):9417-29 [15996096.001]
  • [Cites] Mol Cell Biol. 2005 Oct;25(20):8874-86 [16199867.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Sep 3;321(4):1010-6 [15358129.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6315S-21S [15448024.001]
  • [Cites] J Cell Sci. 2004 Oct 15;117(Pt 22):5283-92 [15454578.001]
  • [Cites] J Biol Chem. 1987 Aug 15;262(23):11389-97 [3301855.001]
  • [Cites] Blood. 1988 Apr;71(4):1033-8 [3258535.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3631-5 [7682714.001]
  • [Cites] Enzyme Protein. 1994-1995;48(1):37-44 [7787969.001]
  • [Cites] Exp Gerontol. 1995 Mar-Apr;30(2):99-124 [8591812.001]
  • [Cites] Exp Cell Res. 1996 Apr 10;224(1):128-35 [8612677.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] FEBS Lett. 1997 Feb 17;403(2):113-5 [9042948.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Mar 17;232(2):503-7 [9125210.001]
  • [Cites] Electrophoresis. 1998 May;19(6):893-900 [9638935.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):1661-72 [10022854.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27 [16204691.001]
  • [Cites] Cell. 2005 Dec 16;123(6):1065-78 [16360036.001]
  • [Cites] J Proteome Res. 2006 Mar;5(3):502-11 [16512664.001]
  • [Cites] Cancer. 2006 May 15;106(10):2284-94 [16604531.001]
  • [Cites] J Cell Biol. 2006 May 8;173(3):395-404 [16651380.001]
  • [Cites] Curr Biol. 2006 Jun 20;16(12):R466-8 [16782004.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(16):6170-84 [16880527.001]
  • [Cites] Nat Biotechnol. 2006 Aug;24(8):971-83 [16900146.001]
  • [Cites] Brief Bioinform. 2006 Jun;7(2):151-8 [16772265.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9705-13 [17018629.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6217s-6221s [17062704.001]
  • [Cites] Oncogene. 2006 Nov 30;25(56):7373-80 [16767159.001]
  • [Cites] Med Sci Monit. 2006 Dec;12(12):CR525-529 [17136009.001]
  • [Cites] J Biol Chem. 2007 Feb 16;282(7):4803-11 [17166848.001]
  • [Cites] Semin Radiat Oncol. 2007 Jul;17(3):169-75 [17591563.001]
  • [Cites] Recent Results Cancer Res. 2007;176:89-120 [17607919.001]
  • [Cites] Am J Pathol. 2007 Aug;171(2):375-85 [17600117.001]
  • [Cites] Drug Discov Today. 2007 Sep;12(17-18):700-8 [17826682.001]
  • [Cites] Leuk Lymphoma. 2008 Apr;49(4):663-76 [18398733.001]
  • [Cites] Am J Pathol. 2008 May;172(5):1381-90 [18403594.001]
  • [Cites] Nature. 2008 Nov 6;456(7218):66-72 [18987736.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Curr Opin Immunol. 2000 Apr;12(2):219-25 [10712950.001]
  • (PMID = 19498000.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR010888-030019; United States / NCI NIH HHS / CA / CA128006; United States / NCRR NIH HHS / RR / RR010888-090116; United States / NCI NIH HHS / CA / CA075107-03; United States / NCRR NIH HHS / RR / P41 RR010888-136129; United States / NCI NIH HHS / CA / CA102889-02; United States / NCI NIH HHS / CA / R03 CA102889-01A1; United States / NCI NIH HHS / CA / R01 CA084193; United States / NCRR NIH HHS / RR / RR010888-136129; United States / NCI NIH HHS / CA / R29 CA075107-04; United States / NCRR NIH HHS / RR / RR010888-107084; United States / NCRR NIH HHS / RR / P41 RR010888-080116; United States / NHLBI NIH HHS / HV / N01-HV-28178; United States / NCI NIH HHS / CA / CA075107-04; United States / NCI NIH HHS / CA / R03 CA128006-01; United States / NCI NIH HHS / CA / R29 CA075107-03; United States / NCI NIH HHS / CA / R03 CA128006; United States / NHLBI NIH HHS / HL / N01HV28178; United States / NCRR NIH HHS / RR / RR010888-040020; United States / NCRR NIH HHS / RR / P41 RR010888-030019; United States / NCI NIH HHS / CA / R29 CA075107; United States / NCI NIH HHS / CA / R03 CA102889-02; United States / NCI NIH HHS / CA / R03 CA102889; United States / NCRR NIH HHS / RR / RR010888-125184; United States / NCI NIH HHS / CA / CA075107-05; United States / NCRR NIH HHS / RR / P41 RR010888-125184; United States / NCI NIH HHS / CA / R03 CA128006-02; United States / NCRR NIH HHS / RR / RR010888-05S10020; United States / NCRR NIH HHS / RR / P41 RR010888-05S10020; United States / NCRR NIH HHS / RR / RR010888-050020; United States / NCRR NIH HHS / RR / P41 RR010888-118005; United States / NCRR NIH HHS / RR / P41 RR010888-090116; United States / NCRR NIH HHS / RR / RR010888-118005; United States / NCI NIH HHS / CA / CA128006-01; United States / NCRR NIH HHS / RR / P41 RR010888-050020; United States / NCI NIH HHS / CA / CA128006-02; United States / NCRR NIH HHS / RR / P41 RR010888-040020; United States / NCRR NIH HHS / RR / P41 RR010888; United States / NCRR NIH HHS / RR / RR010888-080116; United States / NCRR NIH HHS / RR / P41 RR010888-107084; United States / NCI NIH HHS / CA / CA84193; United States / NCRR NIH HHS / RR / P41-RR10888; United States / NCRR NIH HHS / RR / S10-RR15942; United States / NCI NIH HHS / CA / R29 CA075107-05; United States / NCI NIH HHS / CA / CA102889-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2708791
  •  go-up   go-down


84. Kelloff GJ, Sullivan DM, Wilson W, Cheson B, Juweid M, Mills GQ, Zelenetz AD, Horning SJ, Weber W, Sargent DJ, Dodd L, Korn E, Armitage J, Schilsky R, Christian M, O'connor OA, Wang SJ, Farrell AT, Pazdur R, Graham M, Wahl RL, Larson SM, Kostakoglu L, Daube-Witherspoon M, Gastonis C, Siegel BA, Shankar LK, Lee DB, Higley HR, Sigman CC, Carucci D, Timko D, deGennaro LJ, Sigal E, Barker A, Woodcock J: FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol; 2007 Mar;14(3):330-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET lymphoma demonstration project invitational workshop.
  • The proceedings of a workshop focusing on a project to evaluate the use of fluorodeoxyglucose-positron emission tomography (FDG-PET) as a tool to measure treatment response in non-Hodgkin lymphoma (NHL) are described.
  • Sponsored by the Leukemia & Lymphoma Society, the Foundation of the National Institutes of Health, and the National Cancer Institute, and attended by representatives of the Food and Drug Administration, the Centers for Medicare and Medicaid Services, and scientists and clinical researchers from academia and the pharmaceutical and medical imaging industries, the workshop reviewed the etiology and current standards of care for NHL and proposed the development of a clinical trial to validate FDG-PET imaging techniques as a predictive biomarker for cancer therapy response.
  • As organized under the auspices of the Oncology Biomarker Qualification Initiative, the three federal health agencies and their private sector and nonprofit/advocacy group partners believe that FDG-PET not only demonstrates the potential to be used for the diagnosis and staging of many cancers but in particular can provide an early indication of therapeutic response that is well correlated with clinical outcomes for chemotherapy for this common form of lymphoma.
  • The development of standardized criteria for FDG-PET imaging and establishment of procedures for transmission, storage, quality assurance, and analysis of PET images afforded by this demonstration project could streamline clinical trials of new treatments for more intractable forms of lymphoma and other cancers and, hence, accelerate new drug approvals.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / radionuclide imaging. Positron-Emission Tomography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17307666.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


85. Hirt C, Dölken G, Janz S, Rabkin CS: Distribution of t(14;18)-positive, putative lymphoma precursor cells among B-cell subsets in healthy individuals. Br J Haematol; 2007 Aug;138(3):349-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of t(14;18)-positive, putative lymphoma precursor cells among B-cell subsets in healthy individuals.
  • The t(14;18)(q32;q21) is the characteristic chromosomal translocation of follicular lymphoma (FL).
  • These results suggest that t(14;18) is generated during early B-cell development in the bone marrow and that affected cells may mature and expand in germinal centres. t(14;18)-frequency was highest in IgM memory cells, a B-cell subset that shares immunophenotypic similarities with FL.
  • The significance of these cells as lymphoma precursors or indicators of lymphoma risk remains to be established.
  • [MeSH-minor] Clone Cells. Gene Frequency. Genes, Immunoglobulin. Genes, bcl-2. Humans. Immunologic Memory. Immunophenotyping. Lymphoma, Non-Hodgkin / immunology. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614821.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  •  go-up   go-down


91. Giuriato S, Foisseau M, Dejean E, Felsher DW, Al Saati T, Demur C, Ragab A, Kruczynski A, Schiff C, Delsol G, Meggetto F: Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia. Blood; 2010 May 20;115(20):4061-70
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.
  • NPM-ALK (nucleophosmin-anaplastic lymphoma kinase) and TPM3-ALK (nonmuscular tropomyosin 3-anaplastic lymphoma kinase) are oncogenic tyrosine kinases implicated in the pathogenesis of human ALK-positive lymphoma.
  • We report here the development of novel conditional mouse models for ALK-induced lymphomagenesis, with the use of the tetracycline regulatory system under the control of the EmuSRalpha enhancer/promoter.
  • We also observed the development of skin keratoacanthoma lesions, probably because of aberrant ALK expression in keratinocytes.
  • Thus, our results show (1) that NPM-ALK and TPM3-ALK oncogenes are sufficient for lymphoma/leukemia development and required for tumor maintenance, hence validating ALK as potentially effective therapeutic target; and (2) for the first time, in vivo, the equal tumorigenic potential of the NPM-ALK and TPM3-ALK oncogenic tyrosine kinases.
  • [MeSH-major] Leukemia, B-Cell / pathology. Lymphoma, B-Cell / pathology. Protein-Tyrosine Kinases / genetics. Tropomyosin / genetics

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223922.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / TPM3 protein, human; 0 / Tropomyosin; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  •  go-up   go-down


92. Kassam S, Montoto S: Oncologic, endocrine & metabolic emerging drugs in B-cell non-Hodgkin's lymphoma. Expert Opin Emerg Drugs; 2008 Jun;13(2):323-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncologic, endocrine & metabolic emerging drugs in B-cell non-Hodgkin's lymphoma.
  • BACKGROUND: The incidence of non-Hodgkin's lymphoma, of which B-cell neoplasms are the commonest, has been increasing over the last 20 years.
  • Recently, the focus of drug development has shifted from conventional cytotoxic drugs to molecularly targeted agents and immunotherapy, driven by advances in the understanding of the molecular pathogenesis of these disorders.
  • METHODS: PubMed was used for literature searches and additional drug development data were provided by pharma projects.
  • RESULTS/CONCLUSION: Large numbers of new drugs are at various stages of preclinical and clinical development.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Delivery Systems. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Drug Design. Female. Humans. Immunotherapy. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / physiopathology. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / physiopathology. Male. Recurrence. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537524.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 149
  •  go-up   go-down


93. Lee SY, Kumano K, Nakazaki K, Sanada M, Matsumoto A, Yamamoto G, Nannya Y, Suzuki R, Ota S, Ota Y, Izutsu K, Sakata-Yanagimoto M, Hangaishi A, Yagita H, Fukayama M, Seto M, Kurokawa M, Ogawa S, Chiba S: Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci; 2009 May;100(5):920-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma.
  • Signaling through the Notch1 receptor has a pivotal role in early thymocyte development.
  • Gain of Notch1 function results in the development of T-cell acute lymphoblastic leukemia in a number of mouse experimental models, and activating Notch1 mutations deregulate Notch1 signaling in the majority of human T-cell acute lymphoblastic leukemias.
  • Furthermore, high-density oligonucleotide microarray analysis revealed that some diffuse large B-cell lymphoma cases also have increased copies of the mutated Notch2 allele.
  • [MeSH-major] Gene Dosage / genetics. Lymphoma, Large B-Cell, Diffuse / metabolism. Receptor, Notch2 / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetics Home Reference. consumer health - NOTCH2 gene.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19445024.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA, Complementary; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / NOTCH2 protein, human; 0 / Receptor, Notch2; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


94. Cillessen SA, Meijer CJ, Notoya M, Ossenkoppele GJ, Oudejans JJ: Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles. J Pathol; 2010 Apr;220(5):509-20
Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common type of adult non-Hodgkin lymphoma and is treated with chemotherapy in combination with rituximab.
  • In order to survive, lymphoma cells depend on disruption of the apoptosis pathway by mutations in apoptosis inducing genes or by continuous expression of anti-apoptotic proteins.
  • The development of molecules targeting these apoptosis inhibitors provides a very promising opportunity to specifically target tumour cells without toxicity to non-malignant cells in DLBCL patients.
  • [MeSH-major] Apoptosis / physiology. Apoptosis Regulatory Proteins / antagonists & inhibitors. Lymphoma, Large B-Cell, Diffuse / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087881.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Neoplasm Proteins
  • [Number-of-references] 119
  •  go-up   go-down


95. Fu K, Iqbal J, Chan WC: Recent advances in the molecular diagnosis of diffuse large B-cell lymphoma. Expert Rev Mol Diagn; 2005 May;5(3):397-408
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in the molecular diagnosis of diffuse large B-cell lymphoma.
  • In this review, recent advances in the molecular diagnosis of diffuse large B-cell lymphoma are highlighted, using examples of how gene expression profiling has been used in disease classification and outcome predictions.
  • The future development of this field and its applications in the clinical arena will also be discussed.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / genetics. Molecular Diagnostic Techniques

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15934816.001).
  • [ISSN] 1744-8352
  • [Journal-full-title] Expert review of molecular diagnostics
  • [ISO-abbreviation] Expert Rev. Mol. Diagn.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA84967
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Number-of-references] 76
  •  go-up   go-down


96. Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM: Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore); 2009 Sep;88(5):284-93
MedlinePlus Health Information. consumer health - Sjogren's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects.
  • We also aimed to identify risk factors for the development of non-Hodgkin lymphoma (NHL) overall and by subtype.
  • Lymphoma was diagnosed in 7.5% (95% confidence interval [CI], 5.4%-10%) of patients.
  • The development of NHL in patients with pSS could be predicted by the presence of simple clinical and laboratory factors at diagnosis: neutropenia (p = 0.041), cryoglobulinemia (p = 0.008), splenomegaly (p = 0.006), lymphadenopathy (p = 0.021), and low C4 levels (p = 0.009).
  • The above set of disease characteristics could predict subsequent development of MZBCL; the presence of lymphocytopenia (p = 0.044) at diagnosis served as a risk factor for the development of a non-MZBCL, most commonly DLBCL.
  • Neutropenia and cryoglobulinemia at diagnosis are significantly associated with an increased risk of lymphoma development.
  • [MeSH-major] Hematologic Diseases / etiology. Lymphoma / etiology. Sjogren's Syndrome / complications
  • [MeSH-minor] Adult. Cohort Studies. Confidence Intervals. Female. Greece / epidemiology. Humans. Hypergammaglobulinemia / epidemiology. Hypergammaglobulinemia / etiology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology. Male. Middle Aged. Multivariate Analysis. Prevalence. Prognosis. Proportional Hazards Models. Retrospective Studies. Statistics as Topic. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Sjogren Syndrome.
  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19745687.001).
  • [ISSN] 1536-5964
  • [Journal-full-title] Medicine
  • [ISO-abbreviation] Medicine (Baltimore)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Sommer AM, Bitz AK, Streckert J, Hansen VW, Lerchl A: Lymphoma development in mice chronically exposed to UMTS-modulated radiofrequency electromagnetic fields. Radiat Res; 2007 Jul;168(1):72-80
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma development in mice chronically exposed to UMTS-modulated radiofrequency electromagnetic fields.
  • The objective of the present study was to investigate whether chronic exposure to EMFs of the UMTS (Universal Mobile Telecommunication System) influences the development of lymphoma in a lymphoma animal model, the AKR/J mouse.
  • Visibly diseased animals or those older than 43 weeks were killed humanely, and tissue slices were examined for metastatic infiltrations and lymphoma type.
  • [MeSH-major] Cell Phones. Cell Transformation, Neoplastic / pathology. Electromagnetic Fields / adverse effects. Lymphoma / pathology. Radio Waves / adverse effects

  • MedlinePlus Health Information. consumer health - Electromagnetic Fields.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17723000.001).
  • [ISSN] 0033-7587
  • [Journal-full-title] Radiation research
  • [ISO-abbreviation] Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


98. Yepes JF, Mozaffari E, Ruprecht A: Case report: B-cell lymphoma of the maxillary sinus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Dec;102(6):792-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: B-cell lymphoma of the maxillary sinus.
  • Similarly, a malignant growth in the early stages of development can produce radiographic patterns in the alveolar process that may resemble inflammation of odontogenic origin.
  • A case of B-cell lymphoma is reported.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Maxillary Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17138183.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Leucci E, Onnis A, Cocco M, De Falco G, Imperatore F, Giuseppina A, Costanzo V, Cerino G, Mannucci S, Cantisani R, Nyagol J, Mwanda W, Iriso R, Owang M, Schurfeld K, Bellan C, Lazzi S, Leoncini L: B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression. Int J Cancer; 2010 Mar 15;126(6):1316-26
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression.
  • Endemic, sporadic and HIV-associated Burkitt lymphoma (BL) all have a B-cell phenotype and a MYC translocation, but a variable association with the Epstein-Barr virus (EBV).
  • [MeSH-major] B-Lymphocytes / metabolism. Burkitt Lymphoma / genetics. Cell Differentiation. MicroRNAs / genetics. RNA Processing, Post-Transcriptional
  • [MeSH-minor] Adolescent. Adult. Blotting, Western. Cell Line, Tumor. Child. Child, Preschool. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Herpesvirus 4, Human / growth & development. Humans. Male. Middle Aged. Repressor Proteins / genetics. Repressor Proteins / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factors / genetics. Transcription Factors / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19530237.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MIRN127 microRNA, human; 0 / MicroRNAs; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / regulatory factor X transcription factors; 138415-26-6 / PRDM1 protein, human
  •  go-up   go-down


100. Kastrup IB, Worm J, Ralfkiaer E, Hokland P, Guldberg P, Grønbaek K: Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma. Eur J Haematol; 2008 Jan;80(1):61-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma.
  • Here, we examined RFC for mutations and promoter hypermethylation in (i) the inherently MTX-resistant lymphoma cell line (RL);.
  • (ii) 30 paired cases of acute lymphoblastic leukemia (ALL) obtained at diagnosis and at relapse after treatment with MTX; and (iii) 25 cases of diffuse large B-cell lymphoma (DLBCL) at diagnosis, none of which had been previously exposed to MTX.
  • In DLBCL, genetic and epigenetic alterations of RFC were detected at diagnosis in the absence of a selective MTX pressure, suggesting that these alterations may possibly contribute to the development of lymphoma.
  • [MeSH-major] Epigenesis, Genetic. Lymphoma, Large B-Cell, Diffuse / genetics. Membrane Transport Proteins / genetics. Mutation
  • [MeSH-minor] Adolescent. Adult. Biopsy. Child. Child, Preschool. Codon, Nonsense. DNA Methylation. DNA Mutational Analysis. Drug Resistance, Neoplasm / genetics. Female. Humans. Male. Methotrexate. Middle Aged. Mutation, Missense. Point Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Promoter Regions, Genetic. Reduced Folate Carrier Protein

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Haematol. 2008 Apr;80(4):365 [18194482.001]
  • (PMID = 18028428.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Codon, Nonsense; 0 / Membrane Transport Proteins; 0 / Reduced Folate Carrier Protein; 0 / SLC19A1 protein, human; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement